Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 1993 - 1996
  • Medical Resident, Medicine, University of Washington 1990 - 1993
  • M.D., Yale University 1990
• 

  Duke Appointment History

  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2008 - 2012
  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2004 - 2008
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 1999 - 2004
  • Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1996 - 1999
  • Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 1996
• Research
• 

  Selected Grants

  • A Phase III Randomized, Double-Blind, Placebo Controlled, Multi-centre Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative awarded by AstraZeneca AB 2019 - 2024
  • A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Studyof Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellula awarded by AstraZeneca AB 2019 - 2024
  • Beyond PD1: An immunotherapeutic strategy to stimulate and enable both T-cell and B-cell responses in immunosuppressive and non-mutated metastatic breast cancer awarded by Department of Defense 2020 - 2024
  • Preventing Inflammatory Breast Cancer Metastases by Interrupting Cellular Stress Signaling in Lymphatic Emboli and Circulating Tumor Cell Clusters awarded by Department of Defense 2020 - 2023
  • A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA) awarded by AstraZeneca AB 2018 - 2023
  • An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma awarded by H3 Biomedicine, Inc. 2018 - 2023
  • Phase Ib/II Study of Pembrolizumab with Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET) awarded by Ipsen Biopharmaceuticals, Inc. 2016 - 2022
  • Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy awarded by Department of Defense 2012 - 2021
  • A pilot study of active immunotherapy with CEA (6D) VRP vaccine (AVX701) in patients with stage III colon cancer. awarded by AlphaVax, Inc. 2013 - 2021
  • Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2021
  • UNC - Duke Immunotherapy Training Program awarded by University of North Carolina - Chapel Hill 2020 - 2021
  • Phase Ib/II Study of Pembrolizumab with Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET) awarded by Merck 2017 - 2021
  • A Phase 1/2 open label study of Nivolumab monotherapy or Nivolumab combined with Ipilimumab in subjects with advanced or metastatic solid tumors. awarded by Bristol-Myers Squibb Company 2014 - 2021
  • A phase I/2 open label study of Nivolumab monotherapy or Nivolmab combined with Ipilmumab in subjects with advanced or metastatic solid tumors. awarded by Bristol-Myers Squibb Company 2013 - 2020
  • A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AS SECOND-LINE SYSTEMIC THERAPY awarded by ASLAN Pharmaceuticals 2017 - 2020
  • A Study of fafety tolerabolity and clinical activitiy of MEDI4736 and Tremelimumab administered as monotherapy and in combination to subjects with unresectable heptocellular carcinoma awarded by MedImmune, Inc. 2015 - 2020
  • A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Ge awarded by Halozyme, Inc. 2018 - 2020
  • Detection and Elimination of Oncogenic Signaling Networks in Pre-malignant and Malignant Cells with Magnetic Resonance Imaging awarded by Department of Defense 2012 - 2020
  • A Phase I dose escalation and cohort expansion study of ERY974 awarded by Chugai Pharmaceutical Company, Ltd. 2016 - 2020
  • Characterization of Tumor Immunobiological Factors that Promote Lymphovascular Invasion and Dissemination in Locally Advanced Breast Cancer awarded by Department of Defense 2017 - 2020
  • A Phase 1 multicenter, open label study of enadenotucirev combined with PD-1 inhibitor in subjects with metastatic or advanced epithelial tumors awarded by PsiOxus Therapeutics Ltd. 2018 - 2020
  • A multicenter rendomized open label phase 3 trial to compare the efficacy and safety of Lenvatinib versus Sorafenib in first line treatment of subject with unresectable hepatocellular carcinoma. awarded by Eisai, Inc. 2013 - 2019
  • A Phase III study of pemborlizumab (MK-3475) vs chemotherapy in microstatellite instablility - High (MSI-H) or mismatch repair deficienct (dMMR) stage IV colorectal carcinoma (Keynote - 177) awarded by Merck Sharp & Dohme 2016 - 2018
  • A phase 2B randomized controlled multicenter open-label study of the efficacy and immune responsoe of GVAX pancreas vaccine with cyclophosphamide and CRS-207 compared to chemotherapy awarded by Aduro BioTech 2014 - 2018
  • Targeting the WNT/beta-catenin Pathway in Triple Negative Breast Cancer awarded by Department of Defense 2013 - 2018
  • An Open label single arm phase I study of the pahramcokinetics and safety of Carfilzomib in subjects with advanced malignancies and varing degrees of hepatic impairment. awarded by Onyx Pharmaceuticals, Inc 2013 - 2018
  • Long term follow up of subject who participated in aduro sponsored protocols awarded by Aduro BioTech 2015 - 2017
  • Novel Immune Modulating Cellular Vaccine for Prostate Cancer Immunotherapy awarded by Department of Defense 2013 - 2017
  • A Phase 3 randomized placebo contolled parellel-group multicenter double blined study to evaluate the efficacy and safetyof Telotristat Etiprate awarded by Lexicon Pharmaceuticals 2014 - 2015
  • Using Aptamer Coated Nanoparticles Encapsulating Prostate Tumor Antigen Encoding mRNA to Target Dendritic Cells In Vivo awarded by Department of Defense 2012 - 2015
  • Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
  • Targeting hCG-beta for Breast Cancer Immunotherapy awarded by National Institutes of Health 2004 - 2009
  • Vaccination with Regulatory T Cell Depletion awarded by National Institutes of Health 2006 - 2008
  • Biomarker Studies for Novel Anti-Cancer Agents awarded by National Institutes of Health 2003 - 2008
  • Immunotherapy using peptide MHC tetramer isolated Tcells awarded by National Institutes of Health 2002 - 2007
  • Dendritic Cell Mobilization and Active Immunotherapy awarded by National Institutes of Health 2001 - 2007
  • Planning a Duke Academic Public Private Partnership Program (AP4) Center awarded by National Cancer Institute 2004 - 2006
  • Cancer Care Quality Measures: Diagnosis and Treatment of Colorectal Cancer awarded by Agency for Healthcare Research and Quality 2004 - 2005
  • Dexasome Based Immunotherapy of Lung Cancer awarded by National Institutes of Health 2001 - 2004
  • Immunotherapy with TRICOM Modified Dendritic Cells awarded by National Institutes of Health 2001 - 2003
• 

  External Relationships

  • Advanced accelerator Applications
  • Adventist Health System
  • Agios Pharmaceuticals
  • Alphasites
  • American Society of Clinical Oncology
  • Bayer
  • Best Doctors
  • Celgene Corporation
  • Celldex
  • Clovis Oncology
  • Decision Resources, Inc.
  • Defined Health
  • Eisai Pharmaceuticals
  • Exelixis, Inc.
  • Genentech, Inc (Roche Holding)
  • Genzyme Corporation (Sanofi Aventis)
  • Gerson Lehrman Group, Inc.
  • Guardant Health
  • Guidepoint Global
  • Health Advances
  • IPSEN Innovation
  • Intellisphere
  • Lexicon Pharmaceuticals, Inc.
  • MEDACorp (Leerink Swann & Co)
  • Merck & Co. USA (not assoc'd with Merck KGaA)
  • Mylan
  • Mylan
  • Novartis
  • PPD, Inc.
  • Quintiles-Iqvia
  • Schlesinger Associates
  • Society for immunotherapy of cancer
  • Taiho
  • Xcenda, LLC (AmerisourceBergen Corp)
  • adventist
• Publications & Artistic Works
• 

  Selected Publications

  • Books

    • Morse, M. A., and J. M. Llovet. Emerging Therapies: Introduction, 2009. https://doi.org/10.1002/9781444317053.
       Full Text

  • Academic Articles

    • Crosby, Erika J., Amy C. Hobeika, Donna Niedzwiecki, Christel Rushing, David Hsu, Peter Berglund, Jonathan Smith, et al. “Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio.” J Immunother Cancer 8, no. 2 (November 2020). https://doi.org/10.1136/jitc-2020-001662.
       Full Text  Link to Item
    • Smith, V. L., R. C. Bentley, M. A. Morse, and A. A. Pendse. “Unique presentation of a gastrointestinal stromal tumor, epithelioid type, with a dual copy loss of SDHA gene as a liver primary.” Human Pathology: Case Reports 22 (November 1, 2020). https://doi.org/10.1016/j.ehpc.2020.200427.
       Full Text
    • Eads, Jennifer R., Diane Reidy-Lagunes, Heloisa P. Soares, Jennifer A. Chan, Lowell B. Anthony, Thorvardur R. Halfdanarson, Boris G. Naraev, et al. “Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors.” Pancreas 49, no. 9 (October 2020): 1123–30. https://doi.org/10.1097/MPA.0000000000001658.
       Full Text  Link to Item
    • Strosberg, Jonathan, Pamela L. Kunz, Andrew Hendifar, James Yao, David Bushnell, Matthew H. Kulke, Richard P. Baum, et al. “Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.” Eur J Nucl Med Mol Imaging 47, no. 10 (September 2020): 2372–82. https://doi.org/10.1007/s00259-020-04709-x.
       Full Text  Link to Item
    • Kim, Richard D., Nilofer S. Azad, Michael A. Morse, Elizabeth Poplin, Amit Mahipal, Benjamin Tan, Sharon A. Mavroukakis, et al. “Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer.” Clin Cancer Res 26, no. 14 (July 15, 2020): 3557–64. https://doi.org/10.1158/1078-0432.CCR-20-0426.
       Full Text  Link to Item
    • Wang, Shuo, Xiaoli Wang, Xinna Zhou, Herbert Kim Lyerly, Michael A. Morse, and Jun Ren. “DC-CIK as a widely applicable cancer immunotherapy.” Expert Opin Biol Ther 20, no. 6 (June 2020): 601–7. https://doi.org/10.1080/14712598.2020.1728250.
       Full Text  Link to Item
    • Kaneko, Kensuke, Takuya Osada, Michael A. Morse, William R. Gwin, Joshua D. Ginzel, Joshua C. Snyder, Xiao-Yi Yang, et al. “Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors.” Commun Biol 3, no. 1 (May 8, 2020): 226. https://doi.org/10.1038/s42003-020-0956-7.
       Full Text  Link to Item
    • He, Zixuan, Shuo Wang, Guoliang Qiao, Xiaoli Wang, Xinna Zhou, Siyu Zhu, Yanhua Yuan, et al. “Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites.” Am J Transl Res 12, no. 7 (2020): 3940–52.
       Link to Item
    • Metz, David C., Eric Liu, Vijay N. Joish, Lynn Huynh, Todor I. Totev, Mei Sheng Duh, Kiernan Seth, Susan Giacalone, Pablo Lapuerta, and Michael A. Morse. “Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome.” Cancer Manag Res 12 (2020): 9713–19. https://doi.org/10.2147/CMAR.S276519.
       Full Text  Link to Item
    • Morse, Michael A., Eric Liu, Vijay N. Joish, Lynn Huynh, Mu Cheng, Mei Sheng Duh, Kiernan Seth, Pablo Lapuerta, and David C. Metz. “Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study.” Cancer Manag Res 12 (2020): 6607–14. https://doi.org/10.2147/CMAR.S261257.
       Full Text  Link to Item
    • Morse, Michael A., Howard Hochster, and Al Benson. “Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.” Oncologist 25, no. 1 (January 2020): 33–45. https://doi.org/10.1634/theoncologist.2019-0176.
       Full Text  Link to Item
    • Zhou, Xinna, Guoliang Qiao, Jun Ren, Xiaoli Wang, Shuo Wang, Siyu Zhu, Yanhua Yuan, Michael A. Morse, Amy Hobeika, and Herbert Kim Lyerly. “Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients.” Pain 161, no. 1 (January 2020): 127–34. https://doi.org/10.1097/j.pain.0000000000001702.
       Full Text  Link to Item
    • Huang, Lefu, Guoliang Qiao, Michael A. Morse, Xiaoli Wang, Xinna Zhou, Jiangping Wu, Amy Hobeika, Jun Ren, and Herbert K. Lyerly. “Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer.” Oncol Lett 18, no. 6 (December 2019): 5717–24. https://doi.org/10.3892/ol.2019.10964.
       Full Text  Open Access Copy  Link to Item
    • Morse, Michael A., Michael J. Overman, Leighanne Hartman, Taline Khoukaz, Edith Brutcher, Heinz-Josef Lenz, Ajlan Atasoy, Tong Shangguan, Huanyu Zhao, and Bassel El-Rayes. “Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.” Oncologist 24, no. 11 (November 2019): 1453–61. https://doi.org/10.1634/theoncologist.2019-0129.
       Full Text  Link to Item
    • Qiao, Guoliang, Xiaoli Wang, Xinna Zhou, Michael A. Morse, Jiangping Wu, Shuo Wang, Yuguang Song, et al. “Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors.” Int J Hyperthermia 36, no. sup1 (November 2019): 74–82. https://doi.org/10.1080/02656736.2019.1647350.
       Full Text  Link to Item
    • Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.
       Full Text  Link to Item
    • Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.
       Full Text  Link to Item
    • Lv, Shuzhen, Shuo Wang, Guoliang Qiao, Xiaoli Wang, Xinna Zhou, Fengcai Yan, Yanping Li, et al. “Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast.” Clin Breast Cancer 19, no. 5 (October 2019): e617–23. https://doi.org/10.1016/j.clbc.2019.04.001.
       Full Text  Link to Item
    • Le, Dung T., Vincent J. Picozzi, Andrew H. Ko, Zev A. Wainberg, Hedy Kindler, Andrea Wang-Gillam, Paul Oberstein, et al. “Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).” Clin Cancer Res 25, no. 18 (September 15, 2019): 5493–5502. https://doi.org/10.1158/1078-0432.CCR-18-2992.
       Full Text  Link to Item
    • Marano, A. L., J. M. Clarke, M. A. Morse, A. Shah, W. Barrow, M. A. Selim, R. P. Hall, and A. R. Cardones. “Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.” Br J Dermatol 181, no. 3 (September 2019): 580–83. https://doi.org/10.1111/bjd.17245.
       Full Text  Link to Item
    • Sun, Yuanyuan, Suya Wang, Hainan Yang, Jiangping Wu, Sha Li, Guoliang Qiao, Shuo Wang, et al. “Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth.” Immunotherapy 11, no. 11 (August 2019): 953–66. https://doi.org/10.2217/imt-2019-0055.
       Full Text  Link to Item
    • Weinberg, Benjamin A., Joanne Xiu, Michael R. Lindberg, Anthony F. Shields, Jimmy J. Hwang, Kelsey Poorman, Mohamed E. Salem, et al. “Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.” J Gastrointest Oncol 10, no. 4 (August 2019): 652–62. https://doi.org/10.21037/jgo.2018.08.18.
       Full Text  Link to Item
    • Sharma, Padmanee, Arlene Siefker-Radtke, Filippo de Braud, Umberto Basso, Emiliano Calvo, Petri Bono, Michael A. Morse, et al. “Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.” J Clin Oncol 37, no. 19 (July 1, 2019): 1608–16. https://doi.org/10.1200/JCO.19.00538.
       Full Text  Link to Item
    • Zhao, Y., G. Qiao, X. Wang, Y. Song, X. Zhou, N. Jiang, L. Zhou, et al. “Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).” Clin Transl Oncol 21, no. 6 (June 2019): 721–28. https://doi.org/10.1007/s12094-018-1968-3.
       Full Text  Link to Item
    • Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.” Clin Cancer Res 25, no. 9 (May 1, 2019): 2725–36. https://doi.org/10.1158/1078-0432.CCR-18-3102.
       Full Text  Open Access Copy  Link to Item
    • Wang, Xiaoli, Shuo Wang, Michael A. Morse, Ni Jiang, Yanjie Zhao, Yuguang Song, Lei Zhou, et al. “Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients.” J Thromb Thrombolysis 47, no. 4 (May 2019): 505–11. https://doi.org/10.1007/s11239-019-01844-7.
       Full Text  Link to Item
    • Chawla, Sant P., Howard Bruckner, Michael A. Morse, Nupur Assudani, Frederick L. Hall, and Erlinda M. Gordon. “A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.” Mol Ther Oncolytics 12 (March 29, 2019): 56–67. https://doi.org/10.1016/j.omto.2018.12.005.
       Full Text  Link to Item
    • Fishman, M., J. P. Dutcher, J. I. Clark, A. Alva, G. P. Miletello, B. Curti, Neeraj Agarwal, et al. “Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.” J Immunother Cancer 7, no. 1 (March 27, 2019): 84. https://doi.org/10.1186/s40425-019-0567-3.
       Full Text  Link to Item
    • Qiao, Guoliang, Xiaoli Wang, Lei Zhou, Xinna Zhou, Yuguang Song, Shuo Wang, Lei Zhao, et al. “Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.” Clin Cancer Res 25, no. 5 (March 1, 2019): 1494–1504. https://doi.org/10.1158/1078-0432.CCR-18-2360.
       Full Text  Link to Item
    • Wang, Jiangbo, Xiu-Rong Ren, Hailan Piao, Shengli Zhao, Takuya Osada, Richard T. Premont, Robert A. Mook, Michael A. Morse, Herbert Kim Lyerly, and Wei Chen. “Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.” Biochem J 476, no. 3 (February 8, 2019): 535–46. https://doi.org/10.1042/BCJ20180385.
       Full Text  Link to Item
    • Morse, Michael A., Weijing Sun, Richard Kim, Aiwu Ruth He, Paolo B. Abada, Michelle Mynderse, and Richard S. Finn. “The Role of Angiogenesis in Hepatocellular Carcinoma.” Clin Cancer Res 25, no. 3 (February 1, 2019): 912–20. https://doi.org/10.1158/1078-0432.CCR-18-1254.
       Full Text  Link to Item
    • Kane, Ari, Matthew P. Thorpe, Michael A. Morse, Brandon A. Howard, Jorge D. Oldan, Jason Zhu, Terence Z. Wong, Neil A. Petry, Robert Reiman, and Salvador Borges-Neto. “Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG.” J Nucl Med 59, no. 11 (November 2018): 1708–13. https://doi.org/10.2967/jnumed.117.202150.
       Full Text  Open Access Copy  Link to Item
    • Chino, Fumiko, Sarah Jo Stephens, Steve S. Choi, Daniele Marin, Charles Y. Kim, Michael A. Morse, Devon J. Godfrey, Brian G. Czito, Christopher G. Willett, and Manisha Palta. “The role of external beam radiotherapy in the treatment of hepatocellular cancer.” Cancer 124, no. 17 (September 1, 2018): 3476–89. https://doi.org/10.1002/cncr.31334.
       Full Text  Link to Item
    • Osada, Takuya, Zachary C. Hartman, Junping Wei, Gangjun Lei, Amy C. Hobeika, William R. Gwin, Marcio A. Diniz, et al. “Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.” Breast Cancer Res 20, no. 1 (August 9, 2018): 90. https://doi.org/10.1186/s13058-018-1023-x.
       Full Text  Link to Item
    • Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.” Oncologist 23, no. 7 (July 2018): 782–90. https://doi.org/10.1634/theoncologist.2016-0377.
       Full Text  Link to Item
    • Overman, Michael J., Marc S. Ernstoff, and Michael A. Morse. “Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.” Am Soc Clin Oncol Educ Book 38 (May 23, 2018): 239–47. https://doi.org/10.1200/EDBK_200821.
       Full Text  Link to Item
    • Cohn, Allen, Michael A. Morse, Bert O’Neil, Samuel Whiting, Claire Coeshott, John Ferraro, Donald Bellgrau, David Apelian, and Timothy C. Rodell. “Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial.” J Immunother 41, no. 3 (April 2018): 141–50. https://doi.org/10.1097/CJI.0000000000000219.
       Full Text  Link to Item
    • Evans, Myron K., Michael C. Brown, Joseph Geradts, Xuhui Bao, Timothy J. Robinson, Mohit Kumar Jolly, Peter B. Vermeulen, et al. “XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.” Cancer Res 78, no. 7 (April 1, 2018): 1726–38. https://doi.org/10.1158/0008-5472.CAN-17-1667.
       Full Text  Link to Item
    • Overman, Michael J., Sara Lonardi, Ka Yeung Mark Wong, Heinz-Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, et al. “Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.” J Clin Oncol 36, no. 8 (March 10, 2018): 773–79. https://doi.org/10.1200/JCO.2017.76.9901.
       Full Text  Link to Item
    • Zhou, Xinna, Guoliang Qiao, Xiaoli Wang, Qingkun Song, Michael A. Morse, Amy Hobeika, William R. Gwin, Jun Ren, and H Kim Lyerly. “CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.” Cancer Chemother Pharmacol 81, no. 2 (February 2018): 365–72. https://doi.org/10.1007/s00280-017-3500-9.
       Full Text  Link to Item
    • Crosby, Erika J., Junping Wei, Xiao Yi Yang, Gangjun Lei, Tao Wang, Cong-Xiao Liu, Pankaj Agarwal, et al. “Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.” Oncoimmunology 7, no. 5 (2018): e1421891. https://doi.org/10.1080/2162402X.2017.1421891.
       Full Text  Link to Item
    • Jia, Jingquan, Michael A. Morse, Rebecca J. Nagy, Richard B. Lanman, and John H. Strickler. “Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer.” Front Oncol 8 (2018): 305. https://doi.org/10.3389/fonc.2018.00305.
       Full Text  Link to Item
    • Curti, Brendan, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, et al. “Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.” J Immunother Cancer 5, no. 1 (December 19, 2017): 102. https://doi.org/10.1186/s40425-017-0307-5.
       Full Text  Link to Item
    • Osada, Takuya, Kensuke Kaneko, William R. Gwin, Michael A. Morse, Amy Hobeika, Brian W. Pogue, Zachary C. Hartman, Philip F. Hughes, Timothy Haystead, and H Kim Lyerly. “In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior.” Clin Cancer Res 23, no. 24 (December 15, 2017): 7531–42. https://doi.org/10.1158/1078-0432.CCR-17-1453.
       Full Text  Link to Item
    • Le, Dung T., Vanessa M. Hubbard-Lucey, Michael A. Morse, Christopher R. Heery, Andrea Dwyer, Thomas H. Marsilje, Arthur N. Brodsky, et al. “A Blueprint to Advance Colorectal Cancer Immunotherapies.” Cancer Immunol Res 5, no. 11 (November 2017): 942–49. https://doi.org/10.1158/2326-6066.CIR-17-0375.
       Full Text  Link to Item
    • Jiang, Ni, Guoliang Qiao, Xiaoli Wang, Michael A. Morse, William R. Gwin, Lei Zhou, Yuguang Song, et al. “Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.” Clin Cancer Res 23, no. 17 (September 1, 2017): 5066–73. https://doi.org/10.1158/1078-0432.CCR-17-0492.
       Full Text  Link to Item
    • Overman, Michael J., Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz-Josef Lenz, Michael A. Morse, Jayesh Desai, et al. “Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.” Lancet Oncol 18, no. 9 (September 2017): 1182–91. https://doi.org/10.1016/S1470-2045(17)30422-9.
       Full Text  Link to Item
    • Riedel, Richard F., Kellen L. Meadows, Paula H. Lee, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, et al. “Phase I study of pazopanib plus TH-302 in advanced solid tumors.” Cancer Chemotherapy and Pharmacology 79, no. 3 (March 2017): 611–19. https://doi.org/10.1007/s00280-017-3256-2.
       Full Text
    • Clark, Joseph I., Michael K. K. Wong, Howard L. Kaufman, Gregory A. Daniels, Michael A. Morse, David F. McDermott, Sanjiv S. Agarwala, et al. “Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.” Clin Genitourin Cancer 15, no. 1 (February 2017): 31-41.e4. https://doi.org/10.1016/j.clgc.2016.10.008.
       Full Text  Link to Item
    • Osada, Takuya, Michael A. Morse, Amy Hobeika, Marcio A. Diniz, William R. Gwin, Zachary Hartman, Junping Wei, et al. “Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.” Oncoimmunology 6, no. 6 (2017): e1315495. https://doi.org/10.1080/2162402X.2017.1315495.
       Full Text  Link to Item
    • Ren, Jun, William R. Gwin, Xinna Zhou, Xiaoli Wang, Hongyan Huang, Ni Jiang, Lei Zhou, et al. “Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.” Oncoimmunology 6, no. 4 (2017): e1264563. https://doi.org/10.1080/2162402X.2016.1264563.
       Full Text  Link to Item
    • Alva, Ajjai, Gregory A. Daniels, Michael K. K. Wong, Howard L. Kaufman, Michael A. Morse, David F. McDermott, Joseph I. Clark, et al. “Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.” Cancer Immunol Immunother 65, no. 12 (December 2016): 1533–44. https://doi.org/10.1007/s00262-016-1910-x.
       Full Text  Link to Item
    • Langman, Eun L., Paul V. Suhocki, Herbert I. Hurwitz, Michael A. Morse, Rebecca A. Burbridge, Tony P. Smith, and Charles Y. Kim. “Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden.” J Gastrointest Oncol 7, no. 6 (December 2016): 875–81. https://doi.org/10.21037/jgo.2016.06.13.
       Full Text  Link to Item
    • Pishvaian, Michael, Michael A. Morse, Jennifer McDevitt, Jonathan D. Norton, Song Ren, Gabriel J. Robbie, Patricia C. Ryan, Serguei Soukharev, Haifeng Bao, and Crystal S. Denlinger. “Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.” Clin Colorectal Cancer 15, no. 4 (December 2016): 345–51. https://doi.org/10.1016/j.clcc.2016.07.009.
       Full Text  Link to Item
    • Sharma, Padmanee, Margaret K. Callahan, Petri Bono, Joseph Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi N. Pillai, et al. “Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.” Lancet Oncol 17, no. 11 (November 2016): 1590–98. https://doi.org/10.1016/S1470-2045(16)30496-X.
       Full Text  Link to Item
    • Beg, Muhammad S., Nilofer S. Azad, Sandip P. Patel, Jose Torrealba, Sharon Mavroukakis, Melony A. Beatson, Xue Ping Wang, Philip M. Arlen, and Michael A. Morse. “A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.” Cancer Chemother Pharmacol 78, no. 3 (September 2016): 577–84. https://doi.org/10.1007/s00280-016-3108-5.
       Full Text  Link to Item
    • Quiroga, Dionisia, H Kim Lyerly, and Michael A. Morse. “Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.” Curr Treat Options Oncol 17, no. 8 (August 2016): 41. https://doi.org/10.1007/s11864-016-0414-4.
       Full Text  Link to Item
    • Antonia, Scott J., José A. López-Martin, Johanna Bendell, Patrick A. Ott, Matthew Taylor, Joseph Paul Eder, Dirk Jäger, et al. “Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.” Lancet Oncol 17, no. 7 (July 2016): 883–95. https://doi.org/10.1016/S1470-2045(16)30098-5.
       Full Text  Link to Item
    • Morse, M. A. “The Outlook for Immune Checkpoint Targeting Strategies in Colorectal Cancer.” Current Colorectal Cancer Reports 12, no. 1 (February 1, 2016): 51–56. https://doi.org/10.1007/s11888-016-0309-6.
       Full Text
    • Morse, Michael A. “Immunotherapy for Resected Pulmonary Metastases.” Thoracic Surgery Clinics 26, no. 1 (February 2016): 69–78. https://doi.org/10.1016/j.thorsurg.2015.09.009.
       Full Text
    • Evans, M. K., S. J. Sauer, S. Nath, T. J. Robinson, M. A. Morse, and G. R. Devi. “X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.” Cell Death Dis 7 (January 28, 2016): e2073. https://doi.org/10.1038/cddis.2015.412.
       Full Text  Open Access Copy  Link to Item
    • Roe, Matthew T., Derek D. Cyr, Debra Eckart, Phillip J. Schulte, Michael A. Morse, Kimberly L. Blackwell, Neal E. Ready, et al. “Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.” Eur Heart J 37, no. 4 (January 21, 2016): 412–22. https://doi.org/10.1093/eurheartj/ehv611.
       Full Text  Link to Item
    • Buchbinder, Elizabeth I., Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Sandra Aung, Howard L. Kaufman, Marc S. Ernstoff, et al. “A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.” J Immunother Cancer 4 (2016): 52. https://doi.org/10.1186/s40425-016-0155-8.
       Full Text  Link to Item
    • Wong, Michael K. K., Michael A. Morse, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Gregory A. Daniels, Hong Hua, and Sandra Aung. “Abstract B140: Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: Analysis of data on the current use of HD IL-2.” Trials in Progress, January 2016. https://doi.org/10.1158/2326-6074.cricimteatiaacr15-b140.
       Full Text
    • Morse, Michael A., and H Kim Lyerly. “Checkpoint blockade in combination with cancer vaccines.” Vaccine 33, no. 51 (December 16, 2015): 7377–85. https://doi.org/10.1016/j.vaccine.2015.10.057.
       Full Text  Link to Item
    • Ren, X. R., J. Wang, T. Osada, R. A. Mook, M. A. Morse, L. S. Barak, H. K. Lyerly, and W. Chen. “Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.” Breast Cancer Res 17, no. 1 (December 2015): 528. https://doi.org/10.1186/s13058-015-0528-9.
       Full Text  Link to Item
    • Song, Qing-Kun, Jun Ren, Xin-Na Zhou, Xiao-Li Wang, Guo-Hong Song, Li-Jun Di, Jing Yu, et al. “The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.” Oncotarget 6, no. 38 (December 1, 2015): 41350–59. https://doi.org/10.18632/oncotarget.5534.
       Full Text  Link to Item
    • Calvo, Emiliano, Jose Lopez-Martin, Johanna Bendell, Joseph P. Eder, Matthew Taylor, Patrick A. Ott, M Catherine Pietanza, et al. “NIVOLUMAB (NIVO) MONOTHERAPY OR IN COMBINATION WITH IPILIMUMAB (IPI) FOR TREATMENT OF RECURRENT SMALL CELL LUNG CANCER (SCLC).” Asia Pacific Journal of Clinical Oncology 11 (November 1, 2015): 118–118.
       Link to Item
    • Balint, Joseph P., Elizabeth S. Gabitzsch, Adrian Rice, Yvette Latchman, Younong Xu, Gerald L. Messerschmidt, Arvind Chaudhry, Michael A. Morse, and Frank R. Jones. “Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.” Cancer Immunol Immunother 64, no. 8 (August 2015): 977–87. https://doi.org/10.1007/s00262-015-1706-4.
       Full Text  Link to Item
    • Berinstein, Neil L., Mohan Karkada, Amit M. Oza, Kunle Odunsi, Jeannine A. Villella, John J. Nemunaitis, Michael A. Morse, et al. “Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.” Oncoimmunology 4, no. 8 (August 2015): e1026529. https://doi.org/10.1080/2162402X.2015.1026529.
       Full Text  Link to Item
    • Osada, Takuya, Sandip P. Patel, Scott A. Hammond, Koya Osada, Michael A. Morse, and H Kim Lyerly. “CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.” Cancer Immunol Immunother 64, no. 6 (June 2015): 677–88. https://doi.org/10.1007/s00262-015-1671-y.
       Full Text  Link to Item
    • Osada, Takuya, Koji Nagaoka, Masashi Takahara, Xiao Yi Yang, Cong-Xiao Liu, Hongtao Guo, Kingshuk Roy Choudhury, et al. “Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.” J Immunother 38, no. 4 (May 2015): 155–64. https://doi.org/10.1097/CJI.0000000000000075.
       Full Text  Link to Item
    • Le, Dung T., Andrea Wang-Gillam, Vincent Picozzi, Tim F. Greten, Todd Crocenzi, Gregory Springett, Michael Morse, et al. “Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.” J Clin Oncol 33, no. 12 (April 20, 2015): 1325–33. https://doi.org/10.1200/JCO.2014.57.4244.
       Full Text  Link to Item
    • Ren, Xiu-Rong, Jiangbo Wang, Takuya Osada, Robert A. Mook, Michael A. Morse, Larry S. Barak, Herbert Kim Lyerly, and Wei Chen. “Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.” Breast Cancer Res 17 (February 15, 2015): 20. https://doi.org/10.1186/s13058-015-0528-9.
       Full Text  Link to Item
    • Maier, Sabine, Christine H. Chung, Michael Morse, Thomas Platts-Mills, Leigh Townes, Pralay Mukhopadhyay, Prabhu Bhagavatheeswaran, Jan Racenberg, and Ovidiu C. Trifan. “A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions.” Cancer Med 4, no. 1 (January 2015): 36–42. https://doi.org/10.1002/cam4.333.
       Full Text  Link to Item
    • Wolin, Edward M., Barbara Jarzab, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael A. Morse, Paola Tomassetti, et al. “Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.” Drug Des Devel Ther 9 (2015): 5075–86. https://doi.org/10.2147/DDDT.S84177.
       Full Text  Link to Item
    • Jiang, Betty S., Georgia M. Beasley, Paul J. Speicher, Paul J. Mosca, Michael A. Morse, Brent Hanks, April Salama, and Douglas S. Tyler. “Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma.” Ann Surg Oncol 21, no. 8 (August 2014): 2525–31. https://doi.org/10.1245/s10434-014-3671-0.
       Full Text  Link to Item
    • Rangwala, Fatima, Johanna C. Bendell, Mark F. Kozloff, Christy C. Arrowood, Andrew Dellinger, Jennifer Meadows, Sandra Tourt-Uhlig, et al. “Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.” Invest New Drugs 32, no. 4 (August 2014): 700–709. https://doi.org/10.1007/s10637-014-0089-2.
       Full Text  Link to Item
    • Turaga, K., E. Levine, R. Barone, R. Sticca, N. Petrelli, L. Lambert, G. Nash, et al. “Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States.” Ann Surg Oncol 21, no. 5 (May 2014): 1501–5. https://doi.org/10.1245/s10434-013-3061-z.
       Full Text  Link to Item
    • Strickler, John H., Shannon McCall, Andrew B. Nixon, John C. Brady, Herbert Pang, Christel Rushing, Allen Cohn, et al. “Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.” Invest New Drugs 32, no. 2 (April 2014): 330–39. https://doi.org/10.1007/s10637-013-0042-9.
       Full Text  Link to Item
    • Kaufman, Howard L., Michael K. Wong, Gregory A. Daniels, David F. McDermott, Sandra Aung, James N. Lowder, and Michael A. Morse. “The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).” J Pers Med 4, no. 1 (March 7, 2014): 52–64. https://doi.org/10.3390/jpm4010052.
       Full Text  Link to Item
    • Patel, Sandip P., Takuya Osada, H Kim Lyerly, and Michael A. Morse. “Designing effective vaccines for colorectal cancer.” Immunotherapy 6, no. 8 (2014): 913–26. https://doi.org/10.2217/imt.14.61.
       Full Text  Link to Item
    • Wong, Michael K., Howard L. Kaufman, Gregory A. Daniels, David F. McDermott, Sandra Aung, James N. Lowder, and Michael A. Morse. “Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.” J Immunother Cancer 2 (2014): 20. https://doi.org/10.1186/2051-1426-2-20.
       Full Text  Link to Item
    • Morse, Michael A., Donna Niedzwiecki, John L. Marshall, Christopher Garrett, David Z. Chang, Mebea Aklilu, Todd S. Crocenzi, et al. “A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.” Ann Surg 258, no. 6 (December 2013): 879–86. https://doi.org/10.1097/SLA.0b013e318292919e.
       Full Text  Link to Item
    • Patel, S. P., T. Osada, K. Osada, H. Hurwitz, H. K. Lyerly, and M. A. Morse. “Modulation of immune system inhibitory checkpoints in colorectal cancer.” Current Colorectal Cancer Reports 9, no. 4 (December 1, 2013): 391–97. https://doi.org/10.1007/s11888-013-0184-3.
       Full Text
    • Meadows, Kellen L., Paula H. Lee, Richard F. Riedel, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, Jeffrey Crawford, and Herbert I. Hurwitz. “Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302.” Clinical Trials, November 2013. https://doi.org/10.1158/1535-7163.targ-13-c61.
       Full Text
    • Karabudak, Aykan A., Julie Hafner, Vivekananda Shetty, Songming Chen, Angeles Alvarez Secord, Michael A. Morse, and Ramila Philip. “Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.” J Cancer Res Clin Oncol 139, no. 10 (October 2013): 1757–70. https://doi.org/10.1007/s00432-013-1501-6.
       Full Text  Link to Item
    • Hanks, Brent A., Alisha Holtzhausen, Katherine S. Evans, Rebekah Jamieson, Petra Gimpel, Olivia M. Campbell, Melissa Hector-Greene, et al. “Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.” J Clin Invest 123, no. 9 (September 2013): 3925–40. https://doi.org/10.1172/JCI65745.
       Full Text  Open Access Copy  Link to Item
    • Swaminathan, M. S. “Foreword.” Agricultural Sustainability, August 27, 2013. https://doi.org/10.1016/B978-0-12-404560-6.00019-8.
       Full Text
    • Morse, Michael A., Arvind Chaudhry, Elizabeth S. Gabitzsch, Amy C. Hobeika, Takuya Osada, Timothy M. Clay, Andrea Amalfitano, et al. “Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.” Cancer Immunol Immunother 62, no. 8 (August 2013): 1293–1301. https://doi.org/10.1007/s00262-013-1400-3.
       Full Text  Link to Item
    • Patel, Sandip Pravin, Andrew Bristol, Olga Saric, Xue-Ping Wang, Alex Dubeykovskiy, Philip M. Arlen, and Michael A. Morse. “Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.” Cancer Immunol Immunother 62, no. 6 (June 2013): 1011–19. https://doi.org/10.1007/s00262-013-1420-z.
       Full Text  Link to Item
    • Uronis, Hope E., Stephanie M. Cushman, Johanna C. Bendell, Gerard C. Blobe, Michael A. Morse, Andrew B. Nixon, Andrew Dellinger, et al. “A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.” Cancer Med 2, no. 3 (June 2013): 316–24. https://doi.org/10.1002/cam4.65.
       Full Text  Open Access Copy  Link to Item
    • Aggarwal, C., N. J. Meropol, C. J. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath, N. Y. Gabrail, et al. “Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer.” Ann Oncol 24, no. 2 (February 2013): 420–28. https://doi.org/10.1093/annonc/mds336.
       Full Text  Link to Item
    • Allensworth, Jennifer L., Scott J. Sauer, H Kim Lyerly, Michael A. Morse, and Gayathri R. Devi. “Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.” Breast Cancer Res Treat 137, no. 2 (January 2013): 359–71. https://doi.org/10.1007/s10549-012-2352-6.
       Full Text  Open Access Copy  Link to Item
    • Morse, Michael A., Elizabeth S. Gabitzsch, Younong Xu, Dua Rajesh, Susan Nguyen, Stephanie Balcaitis, Joseph P. Balint, and Frank Jones. “Abstract A29: An Ad5 [E1-, E2b-] platform carrying the TAA CEA(6D) induces CEA directed CMI responses in patients with advanced CEA-expressing colorectal cancer in a phase I/II clinical trial..” Combinatorial Immune Based Therapies, January 1, 2013. https://doi.org/10.1158/1538-7445.tumimm2012-a29.
       Full Text
    • Morse, Michael A., Takuya Osada, Amy Hobeika, Sandip Patel, and H Kim Lyerly. “Biomarkers and correlative endpoints for immunotherapy trials.” Am Soc Clin Oncol Educ Book, 2013. https://doi.org/10.1200/EdBook_AM.2013.33.e287.
       Full Text  Link to Item
    • Nair, Smita, Amy J. Aldrich, Eoin McDonnell, Qing Cheng, Anshu Aggarwal, Pujan Patel, Monique M. Williams, et al. “Immunologic targeting of FOXP3 in inflammatory breast cancer cells.” Plos One 8, no. 1 (2013): e53150. https://doi.org/10.1371/journal.pone.0053150.
       Full Text  Link to Item
    • Patel, S. P., T. Osada, K. Osada, H. Hurwitz, H. K. Lyerly, and M. A. Morse. “Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer.” Current Colorectal Cancer Reports, 2013, 1–7.
    • Uronis, Hope E., Johanna C. Bendell, Ivy Altomare, Gerard C. Blobe, S David Hsu, Michael A. Morse, Herbert Pang, et al. “A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.” Oncologist 18, no. 3 (2013): 271–72. https://doi.org/10.1634/theoncologist.2012-0404.
       Full Text  Link to Item
    • Osada, Takuya, Peter Berglund, Michael A. Morse, Bolyn Hubby, Whitney Lewis, Donna Niedzwiecki, Xiao Yi Yang, et al. “Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.” Cancer Immunol Immunother 61, no. 11 (November 2012): 1941–51. https://doi.org/10.1007/s00262-012-1248-y.
       Full Text  Link to Item
    • Roe, Matthew T., Paul W. Armstrong, Keith A. A. Fox, Harvey D. White, Dorairaj Prabhakaran, Shaun G. Goodman, Jan H. Cornel, et al. “Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.” N Engl J Med 367, no. 14 (October 4, 2012): 1297–1309. https://doi.org/10.1056/NEJMoa1205512.
       Full Text  Link to Item
    • Rangwala, Fatima, Kevin P. Williams, Ginger R. Smith, Zainab Thomas, Jennifer L. Allensworth, H Kim Lyerly, Anna Mae Diehl, Michael A. Morse, and Gayathri R. Devi. “Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.” Bmc Cancer 12 (September 10, 2012): 402. https://doi.org/10.1186/1471-2407-12-402.
       Full Text  Link to Item
    • Morse, Michael A., Brent A. Hanks, Paul Suhocki, Phuong L. Doan, Emily A. Liu, Patricia Frost, Stephen A. Bernard, Andrea Tsai, Dominic T. Moore, and Bert H. O’Neil. “Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma.” Clin Colorectal Cancer 11, no. 3 (September 2012): 185–90. https://doi.org/10.1016/j.clcc.2011.11.003.
       Full Text  Link to Item
    • Berinstein, Neil L., Mohan Karkada, Michael A. Morse, John J. Nemunaitis, Gurkamal Chatta, Howard Kaufman, Kunle Odunsi, et al. “First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.” J Transl Med 10 (August 3, 2012): 156. https://doi.org/10.1186/1479-5876-10-156.
       Full Text  Link to Item
    • Strickler, John H., Alexander N. Starodub, Jingquan Jia, Kellen L. Meadows, Andrew B. Nixon, Andrew Dellinger, Michael A. Morse, et al. “Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 2 (August 2012): 251–58. https://doi.org/10.1007/s00280-012-1911-1.
       Full Text  Link to Item
    • Kim, Mickey K., Takuya Osada, William T. Barry, Xiao Yi Yang, Jennifer A. Freedman, Katherine A. Tsamis, Michael Datto, et al. “Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.” Mol Cancer Ther 11, no. 7 (July 2012): 1500–1509. https://doi.org/10.1158/1535-7163.MCT-11-0937.
       Full Text  Link to Item
    • Vlahovic, Gordana, Kellen L. Meadows, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, Richard F. Riedel, S Yousuf Zafar, et al. “A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 1 (July 2012): 95–102. https://doi.org/10.1007/s00280-012-1889-8.
       Full Text  Link to Item
    • Wong, Nan Soon, and Michael A. Morse. “Lonafarnib for cancer and progeria.” Expert Opin Investig Drugs 21, no. 7 (July 2012): 1043–55. https://doi.org/10.1517/13543784.2012.688950.
       Full Text  Link to Item
    • Ren, Xiu-Rong, Junping Wei, Gangjun Lei, Jiangbo Wang, Jiuyi Lu, Wenle Xia, Neil Spector, et al. “Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.” Breast Cancer Res 14, no. 3 (June 7, 2012): R89. https://doi.org/10.1186/bcr3204.
       Full Text  Link to Item
    • Osada, Takuya, Michael A. Morse, Amy Hobeika, and H Kim Lyerly. “Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy.” Semin Oncol 39, no. 3 (June 2012): 305–10. https://doi.org/10.1053/j.seminoncol.2012.02.013.
       Full Text  Link to Item
    • Golden, Keith, John Paul Mounsey, Eugene Chung, Pahresah Roomiani, Michael Andew Morse, Ankit Patel, and Anil Gehi. “Atrial fibrillation ablation using a closed irrigation radiofrequency ablation catheter.” Pacing Clin Electrophysiol 35, no. 5 (May 2012): 506–16. https://doi.org/10.1111/j.1540-8159.2011.03309.x.
       Full Text  Link to Item
    • Morse, M. A., A. Hobeika, D. Serra, K. Aird, M. McKinney, A. Aldrich, T. Clay, et al. “Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.” Cancer Gene Ther 19, no. 1 (January 2012): 30–37. https://doi.org/10.1038/cgt.2011.63.
       Full Text  Link to Item
    • Uronis, Joshua M., Takuya Osada, Shannon McCall, Xiao Yi Yang, Christopher Mantyh, Michael A. Morse, H Kim Lyerly, Bryan M. Clary, and David S. Hsu. “Histological and molecular evaluation of patient-derived colorectal cancer explants.” Plos One 7, no. 6 (2012): e38422. https://doi.org/10.1371/journal.pone.0038422.
       Full Text  Link to Item
    • Hamilton, E. P., A. C. Hobeika, H. K. Lyerly, K. Owzar, G. Rocha, G. G. Kimmick, P. K. Marcom, J. M. Peppercorn, M. A. Morse, and K. L. Blackwell. “P1-13-03: Zoledronic Acid Induces an Immune Response in Breast Cancer Patients through Stimulation of Central Memory and Effector Memory gamma/delta T-Cells.” Poster Session Abstracts, December 15, 2011. https://doi.org/10.1158/0008-5472.sabcs11-p1-13-03.
       Full Text
    • Pruitt, Scott K., David Boczkowski, Nicole de Rosa, N Rebecca Haley, Michael A. Morse, Douglas S. Tyler, Jens Dannull, and Smita Nair. “Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.” Eur J Immunol 41, no. 12 (December 2011): 3553–63. https://doi.org/10.1002/eji.201141383.
       Full Text  Link to Item
    • Hartman, Zachary C., Junping Wei, Oliver K. Glass, Hongtao Guo, Gangjun Lei, Xiao-Yi Yang, Takuya Osada, et al. “Increasing vaccine potency through exosome antigen targeting.” Vaccine 29, no. 50 (November 21, 2011): 9361–67. https://doi.org/10.1016/j.vaccine.2011.09.133.
       Full Text  Link to Item
    • Ghafoori, A Paiman, John W. Nelson, Christopher G. Willett, Junzo Chino, Douglas S. Tyler, Herbert I. Hurwitz, Hope E. Uronis, Michael A. Morse, Robert W. Clough, and Brian G. Czito. “Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma.” Int J Radiat Oncol Biol Phys 81, no. 3 (November 1, 2011): 654–59. https://doi.org/10.1016/j.ijrobp.2010.06.018.
       Full Text  Link to Item
    • Wong, Nan Soon, Kellen L. Meadows, Lee S. Rosen, Alex A. Adjei, Scott H. Kaufmann, Michael A. Morse, William P. Petros, et al. “A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.” Cancer Invest 29, no. 9 (November 2011): 617–25. https://doi.org/10.3109/07357907.2011.621912.
       Full Text  Link to Item
    • Pruitt, S. K., D. Boczkowski, N. de Rosa, N. R. Haley, M. A. Morse, D. S. Tyler, J. Dannull, and S. Nair. “Enhancement of Anti-Tumor Immunity Through Local Modulation of CTLA-4 and GITR by Dendritic Cells.” Eur J Immunol, September 9, 2011. https://doi.org/10.1002/eji.201041383.
       Full Text  Link to Item
    • Wong, Nan Soon, Nishan H. Fernando, Johanna C. Bendell, Michael A. Morse, Gerard C. Blobe, Wanda Honeycutt, Herbert Pang, and Herbert I. Hurwitz. “A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.” Clin Colorectal Cancer 10, no. 3 (September 2011): 210–16. https://doi.org/10.1016/j.clcc.2011.03.018.
       Full Text  Link to Item
    • Morse, Michael A., Robert Chapman, John Powderly, Kimberly Blackwell, Tibor Keler, Jennifer Green, Renee Riggs, et al. “Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.” Clin Cancer Res 17, no. 14 (July 15, 2011): 4844–53. https://doi.org/10.1158/1078-0432.CCR-11-0891.
       Full Text  Link to Item
    • Hartman, Zachary C., Xiao-Yi Yang, Oliver Glass, Gangjun Lei, Takuya Osada, Sandeep S. Dave, Michael A. Morse, Timothy M. Clay, and Herbert K. Lyerly. “HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.” Cancer Res 71, no. 13 (July 1, 2011): 4380–91. https://doi.org/10.1158/0008-5472.CAN-11-0308.
       Full Text  Link to Item
    • Osada, Takuya, Minyong Chen, Xiao Yi Yang, Ivan Spasojevic, Jeffrey B. Vandeusen, David Hsu, Bryan M. Clary, et al. “Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.” Cancer Res 71, no. 12 (June 15, 2011): 4172–82. https://doi.org/10.1158/0008-5472.CAN-10-3978.
       Full Text  Link to Item
    • Hansen, Nicole L., Divya V. Chandiramani, Michael A. Morse, David Wei, Nancy E. Hedrick, and Richard A. Hansen. “Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center.” J Oncol Pharm Pract 17, no. 2 (June 2011): 125–30. https://doi.org/10.1177/1078155209360853.
       Full Text  Link to Item
    • Morse, Michael A., Deborah A. Bradley, Tibor Keler, Robert J. Laliberte, Jennifer A. Green, Thomas A. Davis, and Brant A. Inman. “CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.” Expert Rev Vaccines 10, no. 6 (June 2011): 733–42. https://doi.org/10.1586/erv.11.20.
       Full Text  Link to Item
    • Morse, Michael A., Angeles A. Secord, Kimberly Blackwell, Amy C. Hobeika, Gomathinayagam Sinnathamby, Takuya Osada, Julie Hafner, et al. “MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.” Clin Cancer Res 17, no. 10 (May 15, 2011): 3408–19. https://doi.org/10.1158/1078-0432.CCR-10-2614.
       Full Text  Link to Item
    • Sanoff, H. K., S. Bernard, R. M. Goldberg, M. A. Morse, R. Garcia, L. Woods, D. T. Moore, and B. H. O’Neil. “Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma.” Gastrointestinal Cancer Research 4, no. 3 (May 1, 2011): 78–83.
    • Shetty, Vivekananda, Gomathinayagam Sinnathamby, Zacharie Nickens, Punit Shah, Julie Hafner, Lisa Mariello, Shivali Kamal, et al. “MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response.” J Proteomics 74, no. 5 (May 1, 2011): 728–43. https://doi.org/10.1016/j.jprot.2011.02.020.
       Full Text  Link to Item
    • Clay, Timothy M., Takuya Osada, Zachary C. Hartman, Amy Hobeika, Gayathri Devi, Michael A. Morse, and H Kim Lyerly. “Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.” Immunol Res 49, no. 1–3 (April 2011): 235–47. https://doi.org/10.1007/s12026-010-8186-6.
       Full Text  Link to Item
    • Sinnathamby, G., J. Zerfass, J. Hafner, P. Block, Z. Nickens, A. Hobeika, A. A. Secord, H. K. Lyerly, M. A. Morse, and R. Philip. “ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.” Clin Exp Immunol 163, no. 3 (March 2011): 324–32. https://doi.org/10.1111/j.1365-2249.2010.04298.x.
       Full Text  Link to Item
    • Bullock, Karen E., William P. Petros, Islam Younis, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, S Yousuf Zafar, et al. “A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).” Cancer Chemother Pharmacol 67, no. 2 (February 2011): 465–74. https://doi.org/10.1007/s00280-010-1507-6.
       Full Text  Link to Item
    • Castaneda, Carlos, Kellen L. Meadows, Roxanne Truax, Michael A. Morse, Scott H. Kaufmann, William P. Petros, Yali Zhu, Paul Statkevich, David L. Cutler, and Herbert I. Hurwitz. “Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.” Cancer Chemother Pharmacol 67, no. 2 (February 2011): 455–63. https://doi.org/10.1007/s00280-010-1488-5.
       Full Text  Link to Item
    • Altomare, Ivy, Johanna C. Bendell, Karen E. Bullock, Hope E. Uronis, Michael A. Morse, S David Hsu, S Yousuf Zafar, et al. “A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.” Oncologist 16, no. 8 (2011): 1131–37. https://doi.org/10.1634/theoncologist.2011-0078.
       Full Text  Link to Item
    • Hobeika, Amy C., Michael A. Morse, Takuya Osada, Sharon Peplinski, H Kim Lyerly, and Timothy M. Clay. “Depletion of human regulatory T cells.” Methods Mol Biol 707 (2011): 219–31. https://doi.org/10.1007/978-1-61737-979-6_14.
       Full Text  Link to Item
    • Wong, Nan Soon, Nishan H. Fernando, Andrew B. Nixon, Stephanie Cushman, Mebea Aklilu, Johanna C. Bendell, Michael A. Morse, et al. “A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.” Anticancer Res 31, no. 1 (January 2011): 255–61.
       Link to Item
    • Hanks, Brent A., and Michael A. Morse. “Pharmacological inhibition of TGFβ as a strategy to augment the antitumor immune response.” Curr Opin Investig Drugs 11, no. 12 (December 2010): 1342–53.
       Link to Item
    • Merika, E., M. W. Saif, A. Katz, K. Syrigos, and M. Morse. “Review. Colon cancer vaccines: an update.” In Vivo 24, no. 5 (September 2010): 607–28.
       Link to Item
    • Morse, Michael A., Amy C. Hobeika, Takuya Osada, Peter Berglund, Bolyn Hubby, Sarah Negri, Donna Niedzwiecki, et al. “An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.” J Clin Invest 120, no. 9 (September 2010): 3234–41. https://doi.org/10.1172/JCI42672.
       Full Text  Open Access Copy  Link to Item
    • Hsu, David S., Mickey K. Kim, Bala S. Balakumaran, Chaitanya R. Acharya, Carey K. Anders, Tim Clay, H Kim Lyerly, Charles G. Drake, Michael A. Morse, and Phillip G. Febbo. “Immune signatures predict prognosis in localized cancer.” Cancer Invest 28, no. 7 (August 2010): 765–73. https://doi.org/10.3109/07357900903095755.
       Full Text  Link to Item
    • Morse, Michael A., Junping Wei, Zachary Hartman, Wenle Xia, Xiu-Rong Ren, Gangjun Lei, William T. Barry, et al. “Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.” Int J Cancer 126, no. 12 (June 15, 2010): 2893–2903. https://doi.org/10.1002/ijc.24995.
       Full Text  Link to Item
    • Clarke, Jeffrey M., Michael A. Morse, H Kim Lyerly, Timothy Clay, and Tayuka Osada. “Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.” Expert Opin Biol Ther 10, no. 6 (June 2010): 875–83. https://doi.org/10.1517/14712591003798278.
       Full Text  Link to Item
    • Osada, Takuya, David Hsu, Scott Hammond, Amy Hobeika, Gayathri Devi, Timothy M. Clay, H Kim Lyerly, and Michael A. Morse. “Abstract 5338: Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody.” Immunology, April 15, 2010. https://doi.org/10.1158/1538-7445.am10-5338.
       Full Text
    • Peters, Katherine B., Roger McLendon, Michael A. Morse, and James J. Vredenburgh. “Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report.” Case Rep Oncol 3, no. 1 (April 8, 2010): 93–97. https://doi.org/10.1159/000307468.
       Full Text  Link to Item
    • Dugan, Elizabeth, Roxanne Truax, Kellen L. Meadows, Andrew B. Nixon, William P. Petros, Justin Favaro, Nishan H. Fernando, Michael A. Morse, Gerard C. Blobe, and Herbert I. Hurwitz. “A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.” Anticancer Res 30, no. 4 (April 2010): 1251–56.
       Link to Item
    • Hartman, Zachary C., Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, et al. “An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.” Clin Cancer Res 16, no. 5 (March 1, 2010): 1466–77. https://doi.org/10.1158/1078-0432.CCR-09-2549.
       Full Text  Link to Item
    • Morse, Michael A., and Michael Whelan. “A year of successful cancer vaccines points to a path forward.” Curr Opin Mol Ther 12, no. 1 (February 2010): 11–13.
       Link to Item
    • Osada, T., D. Hsu, S. Hammond, A. Hobeika, G. Devi, T. M. Clay, H. K. Lyerly, and M. A. Morse. “Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.” Br J Cancer 102, no. 1 (January 5, 2010): 124–33. https://doi.org/10.1038/sj.bjc.6605364.
       Full Text  Link to Item
    • Zafar, S Yousuf, Jennifer E. Marcello, Jane L. Wheeler, Krista L. Rowe, Michael A. Morse, James E. Herndon, and Amy P. Abernethy. “Treatment-related toxicity and supportive care in metastatic colorectal cancer.” J Support Oncol 8, no. 1 (January 2010): 15–20.
       Link to Item
    • Dugan, Elizabeth, Roxanne Truax, Kellen L. Meadows, Gerald C. Blobe, Michael A. Morse, Nishan H. Fernando, Jon P. Gockerman, William P. Petros, and Herbert I. Hurwitz. “Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.” Anticancer Res 29, no. 12 (December 2009): 5149–53.
       Link to Item
    • Morse, Michael A., Josh W. Todd, and George A. Stouffer. “Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction.” Drugs 69, no. 14 (October 1, 2009): 1945–66. https://doi.org/10.2165/11317670-000000000-00000.
       Full Text  Link to Item
    • Sinnathamby, Gomathinayagam, Peter Lauer, Jennifer Zerfass, Bill Hanson, Aykan Karabudak, Jonathan Krakover, Angeles Alvarez Secord, et al. “Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.” J Immunother 32, no. 8 (October 2009): 856–69. https://doi.org/10.1097/CJI.0b013e3181b0b125.
       Full Text  Link to Item
    • Shah, U., B. O’Neil, J. Allen, R. M. Goldberg, S. Bernard, D. Moore, A. P. Venook, and M. M. Morse. “A phase II study of long-acting octeotride in patients with advanced hepatocellular carcinoma and CLIP score of 3 or higher.” Gastrointestinal Cancer Research 3, no. 2 (September 25, 2009): 45–48.
    • Iversen, Patrick L., Katherine M. Aird, Rebecca Wu, Michael M. Morse, and Gayathri R. Devi. “Cellular uptake of neutral phosphorodiamidate morpholino oligomers.” Curr Pharm Biotechnol 10, no. 6 (September 2009): 579–88. https://doi.org/10.2174/138920109789069279.
       Full Text  Link to Item
    • Osada, T., X. Y. Yang, Z. C. Hartman, O. Glass, B. L. Hodges, D. Niedzwiecki, M. A. Morse, H. K. Lyerly, A. Amalfitano, and T. M. Clay. “Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.” Cancer Gene Ther 16, no. 9 (September 2009): 673–82. https://doi.org/10.1038/cgt.2009.17.
       Full Text  Link to Item
    • Zafar, S Yousuf, Jennifer E. Marcello, Jane L. Wheeler, Krista L. Rowe, Michael A. Morse, James E. Herndon, and Amy P. Abernethy. “Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.” J Oncol Pract 5, no. 5 (September 2009): 228–33. https://doi.org/10.1200/JOP.091010.
       Full Text  Link to Item
    • Johnson, Benjamin, Takuya Osada, Timothy Clay, Herbert Lyerly, and Michael Morse. “Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression.” Curr Mol Med 9, no. 6 (August 2009): 702–7. https://doi.org/10.2174/156652409788970634.
       Full Text  Link to Item
    • Ribas, Antoni, John M. Kirkwood, Michael B. Atkins, Theresa L. Whiteside, William Gooding, Andreas Kovar, Stephen D. Gillies, Oscar Kashala, and Michael A. Morse. “Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.” J Transl Med 7 (July 29, 2009): 68. https://doi.org/10.1186/1479-5876-7-68.
       Full Text  Link to Item
    • Cohen, S. J., C. J. A. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath, N. Y. Gabrail, J. Picus, et al. “Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.” Ann Oncol 20, no. 7 (July 2009): 1223–29. https://doi.org/10.1093/annonc/mdn786.
       Full Text  Link to Item
    • Reddy, Srinevas K., Daria Zorzi, Ying Wei Lum, Andrew S. Barbas, Timothy M. Pawlik, Dario Ribero, Eddie K. Abdalla, et al. “Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis.” Ann Surg Oncol 16, no. 7 (July 2009): 1809–19. https://doi.org/10.1245/s10434-008-0181-y.
       Full Text  Link to Item
    • Bullock, K. E., H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 4080.
       Link to Item
    • Osada, Takuya, Christopher Y. Woo, Matthew McKinney, Xiao Yi Yang, Gangjun Lei, Heather G. Labreche, Zachary C. Hartman, et al. “Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.” Clin Cancer Res 15, no. 8 (April 15, 2009): 2789–96. https://doi.org/10.1158/1078-0432.CCR-08-2589.
       Full Text  Link to Item
    • Morse, Michael A., Joseph Robert Hall, and Janet M. D. Plate. “Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer.” Expert Opin Biol Ther 9, no. 3 (March 2009): 331–39. https://doi.org/10.1517/14712590802715756.
       Full Text  Link to Item
    • Morse, Michael A., and Michael Whelan. “Turning lemons into lemonade: learning from negative studies in cancer immunotherapy.” Curr Opin Mol Ther 11, no. 1 (February 2009): 10–12.
       Link to Item
    • Nelson, John W., A Paiman Ghafoori, Christopher G. Willett, Douglas S. Tyler, Theodore N. Pappas, Bryan M. Clary, Herbert I. Hurwitz, et al. “Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.” Int J Radiat Oncol Biol Phys 73, no. 1 (January 1, 2009): 148–53. https://doi.org/10.1016/j.ijrobp.2008.07.008.
       Full Text  Link to Item
    • Reddy, Srinevas K., Gloria Broadwater, Donna Niedzwiecki, Andrew S. Barbas, Herbert I. Hurwitz, Johanna C. Bendell, Michael A. Morse, and Bryan M. Clary. “Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.” J Gastrointest Surg 13, no. 1 (January 2009): 74–84. https://doi.org/10.1007/s11605-008-0617-5.
       Full Text  Link to Item
    • Khan, M. U., M. Morse, and R. E. Coleman. “Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors.” Q J Nucl Med Mol Imaging 52, no. 4 (December 2008): 441–54.
       Link to Item
    • Morse, Michael A. “Status of colon cancer vaccines. [An interview with Michael Morse by H&O].” Clin Adv Hematol Oncol 6, no. 11 (November 2008): 789–94.
       Link to Item
    • McKinney, M., and M. A. Morse. “Advances in immunotherapy for colorectal malignancies.” Current Colorectal Cancer Reports 4, no. 4 (October 1, 2008): 177–83. https://doi.org/10.1007/s11888-008-0029-7.
       Full Text
    • Barve, Minal, James Bender, Neil Senzer, Casey Cunningham, F Anthony Greco, David McCune, Ronald Steis, et al. “Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 27 (September 2008): 4418–25. https://doi.org/10.1200/jco.2008.16.6462.
       Full Text
    • Morse, M. A., and C. G. Willett. “An odd but synergistic couple: Immunotherapy combined with radiotherapy.” Oncology 22, no. 9 (August 1, 2008): 1075–80.
    • Morse, Michael A., Amy C. Hobeika, Takuya Osada, Delila Serra, Donna Niedzwiecki, H Kim Lyerly, and Timothy M. Clay. “Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.” Blood 112, no. 3 (August 1, 2008): 610–18. https://doi.org/10.1182/blood-2008-01-135319.
       Full Text  Link to Item
    • Osada, Takuya, Gabriel Chong, Robert Tansik, Timothy Hong, Neil Spector, Rakesh Kumar, Herbert I. Hurwitz, et al. “The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.” Cancer Immunol Immunother 57, no. 8 (August 2008): 1115–24. https://doi.org/10.1007/s00262-007-0441-x.
       Full Text  Link to Item
    • Cohen, Steven J., Cornelis J. A. Punt, Nicholas Iannotti, Bruce H. Saidman, Kert D. Sabbath, Nashat Y. Gabrail, Joel Picus, et al. “Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.” J Clin Oncol 26, no. 19 (July 1, 2008): 3213–21. https://doi.org/10.1200/JCO.2007.15.8923.
       Full Text  Link to Item
    • Abernethy, A. P., Y. Zafar, J. Marcello, J. Wheeler, K. Rowe, M. A. Morse, and J. E. Herndon. “Treatment-related toxicity and supportive care in metastatic colorectal cancer (mCRC).” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 15087.
       Link to Item
    • Abernethy, A. P., Y. Zafar, J. Marcello, J. Wheeler, K. Rowe, M. A. Morse, and J. E. Herndon. “Treatment-related toxicity and supportive care in metastatic colorectal cancer (mCRC).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 15087–15087. https://doi.org/10.1200/jco.2008.26.15_suppl.15087.
       Full Text
    • Barve, M., J. Bender, B. Pappen, G. Ishioka, M. A. Morse, F. A. Greco, D. McCune, R. Steis, H. Khong, and J. J. Nemunaitis. “Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 8057–8057. https://doi.org/10.1200/jco.2008.26.15_suppl.8057.
       Full Text
    • Barve, M., J. Bender, B. Pappen, G. Ishioka, M. A. Morse, F. A. Greco, D. McCune, et al. “Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 8057.
       Link to Item
    • Bendell, J. C., H. E. Uronis, M. A. Morse, G. Blobe, M. Aklilu, A. Nixon, D. Niedzweicki, W. Honeycutt, L. Howard, and H. Hurwitz. “Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC).” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 4063.
       Link to Item
    • Bendell, J. C., H. E. Uronis, M. A. Morse, G. Blobe, M. Aklilu, A. Nixon, D. Niedzweicki, W. Honeycutt, L. Howard, and H. Hurwitz. “Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 4063–4063. https://doi.org/10.1200/jco.2008.26.15_suppl.4063.
       Full Text
    • Clay, T. M., A. Hobeika, T. Osada, D. Serra, D. Niedzwiecki, H. K. Lyerly, and M. A. Morse. “Depletion of human regulatory T cells (Treg) and antigen-specific immune responses to cancer vaccines.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 3010.
       Link to Item
    • Hanks, B. A., P. V. Suhocki, D. M. DeLong, P. L. Doan, E. Liu, A. L. Tsai, C. T. Burke, S. A. Bernard, B. H. O’Neil, and M. A. Morse. “The efficacy and tolerability of transarterial chemo-embolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC).” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 4595.
       Link to Item
    • Hanks, B. A., P. V. Suhocki, D. M. DeLong, P. L. Doan, E. Liu, A. L. Tsai, C. T. Burke, S. A. Bernard, B. H. O’Neil, and M. A. Morse. “The efficacy and tolerability of transarterial chemo-embolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 4595–4595. https://doi.org/10.1200/jco.2008.26.15_suppl.4595.
       Full Text
    • Herndon, J. E., Y. Zafar, J. Marcello, J. Wheeler, K. Rowe, M. A. Morse, and A. P. Abernethy. “Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC).” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 15082.
       Link to Item
    • Herndon, J. E., Y. Zafar, J. Marcello, J. Wheeler, K. Rowe, M. A. Morse, and A. P. Abernethy. “Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 15082–15082. https://doi.org/10.1200/jco.2008.26.15_suppl.15082.
       Full Text
    • Morse, M. A., J. W. Babich, N. LaFrance, K. A. Kacena, J. Gockerman, J. Moore, and R. E. Coleman. “A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo).” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 4605.
       Link to Item
    • Morse, M. A., J. W. Babich, N. LaFrance, K. A. Kacena, J. Gockerman, J. Moore, and R. E. Coleman. “A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 4605–4605. https://doi.org/10.1200/jco.2008.26.15_suppl.4605.
       Full Text
    • O’Neil, B. H., S. A. Bernard, R. M. Goldberg, D. T. Moore, R. Garcia, C. Marroquin, M. A. Morse, L. Woods, and H. K. Sanoff. “Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 4604.
       Link to Item
    • O’Neil, B. H., S. A. Bernard, R. M. Goldberg, D. T. Moore, R. Garcia, C. Marroquin, M. A. Morse, L. Woods, and H. K. Sanoff. “Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 4604–4604. https://doi.org/10.1200/jco.2008.26.15_suppl.4604.
       Full Text
    • Uronis, H. E., J. E. Herndon, A. Coan, K. Bronson, J. Wheeler, H. K. Lyerly, M. A. Morse, and A. P. Abernethy. “E/Tablets to collect research-quality, patient-reported data.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 17528.
       Link to Item
    • Maecker, Holden T., Jeffrey Hassler, Janice K. Payne, Amanda Summers, Karrie Comatas, Manar Ghanayem, Michael A. Morse, et al. “Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.” Bmc Immunol 9 (March 17, 2008): 9. https://doi.org/10.1186/1471-2172-9-9.
       Full Text  Link to Item
    • Chung, Christine H., Beloo Mirakhur, Emily Chan, Quynh-Thu Le, Jordan Berlin, Michael Morse, Barbara A. Murphy, et al. “Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.” N Engl J Med 358, no. 11 (March 13, 2008): 1109–17. https://doi.org/10.1056/NEJMoa074943.
       Full Text  Link to Item
    • Whelan, M., and M. A. Morse. “When is an adjuvant not an adjuvant?” Current Opinion in Molecular Therapeutics 10, no. 1 (February 1, 2008): 8–9.
    • Whelan, Michael, and Michael A. Morse. “When is an adjuvant not an adjuvant? Overview.” Curr Opin Mol Ther 10, no. 1 (February 2008): 8–9.
       Link to Item
    • Aird, Katherine M., Xiuyun Ding, Aris Baras, Junping Wei, Michael A. Morse, Timothy Clay, Herbert K. Lyerly, and Gayathri R. Devi. “Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.” Mol Cancer Ther 7, no. 1 (January 2008): 38–47. https://doi.org/10.1158/1535-7163.MCT-07-0370.
       Full Text  Link to Item
    • Hobeika, Ac, T. Osada, D. Serra, S. Peplinski, K. Hanson, Y. Tanaka, D. Niedzwiecki, et al. “Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.” Cytotherapy 10, no. 3 (2008): 289–302. https://doi.org/10.1080/14653240801927040.
       Full Text  Link to Item
    • Morse, Michael. “Comment regarding benefit in phase 1 oncology trials.” Clin Trials 5, no. 6 (2008): 626. https://doi.org/10.1177/1740774508098682.
       Full Text  Link to Item
    • Reddy, Srinevas K., Michael A. Morse, Herbert I. Hurwitz, Johanna C. Bendell, Tong J. Gan, Steven E. Hill, and Bryan M. Clary. “Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.” J Am Coll Surg 206, no. 1 (January 2008): 96–106. https://doi.org/10.1016/j.jamcollsurg.2007.06.290.
       Full Text  Link to Item
    • Kelsey, Chris R., John W. Nelson, Christopher G. Willett, Junzo P. Chino, Robert W. Clough, Johanna C. Bendell, Douglas S. Tyler, et al. “Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.” Int J Radiat Oncol Biol Phys 69, no. 5 (December 1, 2007): 1436–41. https://doi.org/10.1016/j.ijrobp.2007.05.006.
       Full Text  Link to Item
    • Patwardhan, Meenal, Deborah A. Fisher, Christopher R. Mantyh, Douglas C. McCrory, Michael A. Morse, Robert G. Prosnitz, Kathryn Cline, and Gregory P. Samsa. “Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature).” J Eval Clin Pract 13, no. 6 (December 2007): 831–45. https://doi.org/10.1111/j.1365-2753.2006.00762.x.
       Full Text  Link to Item
    • Reddy, Srinevas K., Timothy M. Pawlik, Daria Zorzi, Ana L. Gleisner, Dario Ribero, Lia Assumpcao, Andrew S. Barbas, et al. “Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis.” Ann Surg Oncol 14, no. 12 (December 2007): 3481–91. https://doi.org/10.1245/s10434-007-9522-5.
       Full Text  Link to Item
    • Kelsey, Chris R., Junzo P. Chino, Christopher G. Willett, Robert W. Clough, Herbert I. Hurwitz, Michael A. Morse, Johanna C. Bendell, Thomas A. D’Amico, and Brian G. Czito. “Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.” Int J Radiat Oncol Biol Phys 69, no. 3 (November 1, 2007): 770–76. https://doi.org/10.1016/j.ijrobp.2007.03.035.
       Full Text  Link to Item
    • Clavien, P. A., J. Baillie, M. A. Morse, and M. Selzner. “Diseases of the Gallbladder and Bile Ducts: Diagnosis and Treatment: Second Edition.” Diseases of the Gallbladder and Bile Ducts: Diagnosis and Treatment: Second Edition, October 25, 2007, 1–428. https://doi.org/10.1002/9780470986981.
       Full Text
    • Morse, M. A., and B. Pestalozzi. “Medical and Innovative Therapies for Biliary Malignancies,” October 25, 2007, 205–14. https://doi.org/10.1002/9780470986981.ch11.
       Full Text
    • Saltz, Leonard B., Heinz-Josef Lenz, Hedy L. Kindler, Howard S. Hochster, Scott Wadler, Paulo M. Hoff, Nancy E. Kemeny, et al. “Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.” J Clin Oncol 25, no. 29 (October 10, 2007): 4557–61. https://doi.org/10.1200/JCO.2007.12.0949.
       Full Text  Link to Item
    • Morse, Michael, Lee Langer, Alexander Starodub, Amy Hobeika, Timothy Clay, and H Kim Lyerly. “Current immunotherapeutic strategies in colon cancer.” Surg Oncol Clin N Am 16, no. 4 (October 2007): 873–x. https://doi.org/10.1016/j.soc.2007.07.005.
       Full Text  Link to Item
    • Morse, Michael A., Amy Hobeika, Takuya Osada, Donna Niedzwiecki, Paul Kelly Marcom, Kimberly L. Blackwell, Carey Anders, Gayathri R. Devi, H Kim Lyerly, and Timothy M. Clay. “Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.” J Transl Med 5 (September 6, 2007): 42. https://doi.org/10.1186/1479-5876-5-42.
       Full Text  Link to Item
    • Osada, T., T. M. Clay, C. Y. Woo, M. A. Morse, and H. Kim Lyerly. “Natural killer cell activation and dendritic cell-based vaccines.” Minerva Biotecnologica 19, no. 3 (September 1, 2007): 91–104.
    • Langer, Lee F., Timothy M. Clay, and Michael A. Morse. “Update on anti-CTLA-4 antibodies in clinical trials.” Expert Opin Biol Ther 7, no. 8 (August 2007): 1245–56. https://doi.org/10.1517/14712598.7.8.1245.
       Full Text  Link to Item
    • Murad, Yanal M., Timothy M. Clay, H Kim Lyerly, and Michael A. Morse. “CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.” Expert Opin Biol Ther 7, no. 8 (August 2007): 1257–66. https://doi.org/10.1517/14712598.7.8.1257.
       Full Text  Link to Item
    • Demetri, G. D., R. S. Benjamin, C. D. Blanke, J. Y. Blay, P. Casali, H. Choi, C. L. Corless, et al. “NCCN task force report: Management of patients with Gastrointestinal Stromal Tumor (GIST) - Update of the NCCN clinical practice guidelines.” Jnccn Journal of the National Comprehensive Cancer Network 5, no. SUPPL. 2 (July 20, 2007).
    • Hu, Zhenlin, Xiao Yi Yang, Yunbo Liu, Georgy N. Sankin, Eric C. Pua, Michael A. Morse, H Kim Lyerly, Timothy M. Clay, and Pei Zhong. “Investigation of HIFU-induced anti-tumor immunity in a murine tumor model.” J Transl Med 5 (July 11, 2007): 34. https://doi.org/10.1186/1479-5876-5-34.
       Full Text  Link to Item
    • Demetri, George D., Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L. Corless, et al. “NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.” J Natl Compr Canc Netw 5 Suppl 2 (July 2007): S1-29.
       Link to Item
    • Czito, Brian G., Johanna C. Bendell, Christopher G. Willett, Michael A. Morse, Gerard C. Blobe, Douglas S. Tyler, John Thomas, et al. “Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.” Int J Radiat Oncol Biol Phys 68, no. 2 (June 1, 2007): 472–78. https://doi.org/10.1016/j.ijrobp.2007.02.001.
       Full Text  Link to Item
    • Mosca, Paul J., H Kim Lyerly, Timothy M. Clay, and Michael A. Morse. “Dendritic cell vaccines.” Frontiers in Bioscience : A Journal and Virtual Library 12 (May 2007): 4050–60. https://doi.org/10.2741/2371.
       Full Text
    • Johnson, Benjamin F., Timothy M. Clay, Amy C. Hobeika, H Kim Lyerly, and Michael A. Morse. “Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.” Expert Opin Biol Ther 7, no. 4 (April 2007): 449–60. https://doi.org/10.1517/14712598.7.4.449.
       Full Text  Link to Item
    • Czito, Brian G., Chris R. Kelsey, Herbert I. Hurwitz, Chris G. Willett, Michael A. Morse, Gerard C. Blobe, Nishan H. Fernando, et al. “A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.” Int J Radiat Oncol Biol Phys 67, no. 4 (March 15, 2007): 1002–7. https://doi.org/10.1016/j.ijrobp.2006.10.027.
       Full Text  Link to Item
    • Reddy, Srinevas K., Andrew S. Barbas, Carlos E. Marroquin, Michael A. Morse, Paul C. Kuo, and Bryan M. Clary. “Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis.” J Am Coll Surg 204, no. 3 (March 2007): 372–82. https://doi.org/10.1016/j.jamcollsurg.2006.12.019.
       Full Text  Link to Item
    • Hutchings, Yalonda, Takuya Osada, Christopher Y. Woo, Timothy M. Clay, H Kim Lyerly, and Michael A. Morse. “Immunotherapeutic targeting of Wilms' tumor protein.” Curr Opin Mol Ther 9, no. 1 (February 2007): 62–69.
       Link to Item
    • Morse, M. A., and M. Whelan. “Learning from each other: Applying observations from anti-tumor, anti-pathogen and anti-toxin immunotherapy.” Current Opinion in Molecular Therapeutics 9, no. 1 (February 1, 2007): 10–11.
    • Dalgleish, A., D. Emerich, M. Glassy, R. J. Kreitman, V. Mironov, M. Morse, and D. Santini. “Editorial Board Focus – February 2007.” Expert Opinion on Biological Therapy 7, no. 2 (January 2, 2007): 157–60. https://doi.org/10.1517/14712598.7.2.157.
       Full Text
    • Prosnitz, Robert G., Meenal B. Patwardhan, Gregory P. Samsa, Christopher R. Mantyh, Deborah A. Fisher, Douglas C. McCrory, Kathryn E. Cline, Rebecca N. Gray, and Michael A. Morse. “Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review.” Cancer 107, no. 10 (November 15, 2006): 2352–60. https://doi.org/10.1002/cncr.22278.
       Full Text  Link to Item
    • Osada, T., and M. A. Morse. “Immunization with fowlpox vector-modified dendritic cell in patients with carcinoembryonic antigen-expressing cancer: Phase I clinical study.” Biotherapy 20, no. 6 (November 1, 2006): 541–48.
    • Woo, Christopher Y., Takuya Osada, Timothy M. Clay, H Kim Lyerly, and Michael A. Morse. “Recent clinical progress in virus-based therapies for cancer.” Expert Opin Biol Ther 6, no. 11 (November 2006): 1123–34. https://doi.org/10.1517/14712598.6.11.1123.
       Full Text  Link to Item
    • Morse, M., P. Wu, S. Choi, T. H. Kim, A. S. Brown, M. Losurdo, and G. Bruno. “Structural and optical characterization of GaN heteroepitaxial films on SiC substrates.” Applied Surface Science 253, no. 1 SPEC. ISS. (October 31, 2006): 232–35. https://doi.org/10.1016/j.apsusc.2006.05.097.
       Full Text
    • Osada, Takuya, Timothy Clay, Amy Hobeika, H Kim Lyerly, and Michael A. Morse. “NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.” Cancer Immunol Immunother 55, no. 9 (September 2006): 1122–31. https://doi.org/10.1007/s00262-005-0089-3.
       Full Text  Link to Item
    • Osada, Takuya, Timothy M. Clay, Christopher Y. Woo, Michael A. Morse, and H Kim Lyerly. “Dendritic cell-based immunotherapy.” Int Rev Immunol 25, no. 5–6 (September 2006): 377–413. https://doi.org/10.1080/08830180600992456.
       Full Text  Link to Item
    • Toloza, Eric M., Michael A. Morse, and H Kim Lyerly. “Gene therapy for lung cancer.” J Cell Biochem 99, no. 1 (September 1, 2006): 1–22. https://doi.org/10.1002/jcb.20851.
       Full Text  Link to Item
    • Brown, A. S., T. H. Kim, S. Choi, P. Wu, M. Morse, M. Losurdo, M. M. Giangregorio, G. Bruno, and A. Moto. “Growth of InN on 6H-SiC by plasma assisted molecular beam epitaxy.” Physica Status Solidi (C) Current Topics in Solid State Physics 3 (July 31, 2006): 1531–35. https://doi.org/10.1002/pssc.200565150.
       Full Text
    • Kelsey, C. R., B. G. Czito, J. C. Bendell, C. G. Willett, M. A. Morse, T. A. D’Amico, W. Honeycutt, A. Franklin, D. Yu, and H. I. Hurwitz. “A phase I study of capecitabine (CAP), carboplatin (CARB), paclitaxel (TAX) and external beam radiation therapy (EBRT) for patients with esophageal carcinoma (EC).” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 14044.
       Link to Item
    • Losurdo, M., M. M. Giangregorio, G. Bruno, T. H. Kim, P. Wu, S. Choi, M. Morse, et al. “Modification of InN properties by interactions with hydrogen and nitrogen.” Materials Research Society Symposium Proceedings 892 (May 15, 2006): 155–60.
    • Hu, Z., X. Y. Yang, Y. Liu, M. A. Morse, H. K. Lyerly, T. M. Clay, and P. Zhong. “Investigation of HIFU-induced anti-tumor immunity in a murine tumor model.” Aip Conference Proceedings 829 (May 8, 2006): 241–45. https://doi.org/10.1063/1.2205474.
       Full Text
    • Patwardhan, Meenal B., Gregory P. Samsa, Douglas C. McCrory, Deborah A. Fisher, Christopher R. Mantyh, Michael A. Morse, Robert G. Prosnitz, Kathryn E. Cline, and Rebecca N. Gray. “Cancer care quality measures: diagnosis and treatment of colorectal cancer.” Evid Rep Technol Assess (Full Rep), no. 138 (May 2006): 1–116.
       Link to Item
    • Morse, Michael A. “Supportive care in the management of colon cancer.” Support Cancer Ther 3, no. 3 (April 1, 2006): 158–70. https://doi.org/10.3816/SCT.2006.n.014.
       Full Text  Link to Item
    • Bunce, C., and M. A. Morse. “Editorial overview: Fulfilling the promise of immunotherapy.” Current Opinion in Molecular Therapeutics 8, no. 1 (February 1, 2006): 9–10.
    • Bunce, Campbell, and Michael A. Morse. “Fulfilling the promise of immunotherapy.” Curr Opin Mol Ther 8, no. 1 (February 2006): 9–10.
       Link to Item
    • Czito, Brian G., Christopher G. Willett, Johanna C. Bendell, Michael A. Morse, Douglas S. Tyler, Nishan H. Fernando, Christopher R. Mantyh, et al. “Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.” J Clin Oncol 24, no. 4 (February 1, 2006): 656–62. https://doi.org/10.1200/JCO.2005.04.1749.
       Full Text  Link to Item
    • Czito, Brian G., Timothy J. Hong, Darrel P. Cohen, William P. Petros, Douglas S. Tyler, Theodore N. Pappas, Daohai Yu, et al. “A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.” Cancer Invest 24, no. 1 (February 2006): 9–17. https://doi.org/10.1080/07357900500449454.
       Full Text  Link to Item
    • Woo, Christopher Y., Timothy M. Clay, H Kim Lyerly, Michael A. Morse, and Takuya Osada. “Role of natural killer cell function in dendritic cell-based vaccines.” Expert Rev Vaccines 5, no. 1 (February 2006): 55–65. https://doi.org/10.1586/14760584.5.1.55.
       Full Text  Link to Item
    • Lou, E., J. Marshall, M. Aklilu, D. Cole, D. Chang, and M. Morse. “A phase II study of active immunotherapy with PANVAC^TM or autologous, cultured dendritic cells infected with PANVAC^TM after complete resection of hepatic metastases of colorectal carcinoma.” Clinical Colorectal Cancer 5, no. 5 (January 1, 2006): 368–71. https://doi.org/10.3816/CCC.2006.n.009.
       Full Text
    • Chong, Gabriel T., Raymond J. Kim, Srivani R. Ambati, Terence Z. Wong, Louis R. Dibernardo, Elmar M. Merkle, Thomas Ryan, and Michael A. Morse. “Diagnosis of a solitary cardiac metastasis from ocular melanoma.” J Thorac Cardiovasc Surg 130, no. 6 (December 2005): 1727–28. https://doi.org/10.1016/j.jtcvs.2005.07.058.
       Full Text  Link to Item
    • Chong, Gabriel, and Michael A. Morse. “Combining cancer vaccines with chemotherapy.” Expert Opin Pharmacother 6, no. 16 (December 2005): 2813–20. https://doi.org/10.1517/14656566.6.16.2813.
       Full Text  Link to Item
    • Kim, T. H., S. Choi, M. Morse, P. Wu, C. Yi, A. Brown, M. Losurdo, M. M. Giangregorio, and G. Bruno. “Impact of unintentional and intentional nitridation of the 6H-SiC(0001)Si substrate on GaN epitaxy.” Journal of Vacuum Science and Technology B: Microelectronics and Nanometer Structures 23, no. 3 (December 1, 2005): 1181–85. https://doi.org/10.1116/1.1878997.
       Full Text
    • Morse, M. A. “Perspectives in Colorectal Cancer - Sixth Annual Conference. Metastatic colorectal cancer. 23-24 September 2005, Chicago, IL, USA.” Idrugs 8, no. 12 (December 1, 2005): 974–77.
    • Morse, Michael A. “Virus-based therapies for colon cancer.” Expert Opin Biol Ther 5, no. 12 (December 2005): 1627–33. https://doi.org/10.1517/14712598.5.12.1627.
       Full Text  Link to Item
    • Morse, Michael A. “Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.” Idrugs 8, no. 12 (December 2005): 974–77.
       Link to Item
    • Morse, Michael A. “Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.” Curr Opin Mol Ther 7, no. 6 (December 2005): 588–97.
       Link to Item
    • Gans, Henry. “Case 23-2005: a man with a mass in the liver.” N Engl J Med 353, no. 20 (November 17, 2005): 2195–97.
       Link to Item
    • Smith, A. D., M. A. Morse, and P. C. Kuo. “Case 23-2005: A man with a mass in the liver.” New England Journal of Medicine 353, no. 20 (November 17, 2005): 2196–2196.
       Link to Item
    • Brown, A. S., M. Losurdo, T. H. Kim, M. M. Giangregorio, S. Choi, M. Morse, P. Wu, P. Capezzuto, and G. Bruno. “The impact of SiC substrate treatment on the heteroepitaxial growth of GaN by plasma assisted MBE.” Crystal Research and Technology 40, no. 10–11 (November 1, 2005): 997–1002. https://doi.org/10.1002/crat.200410475.
       Full Text
    • Hu, Zhenlin, Xiao Yi Yang, Yunbo Liu, Michael A. Morse, H Kim Lyerly, Timothy M. Clay, and Pei Zhong. “Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs.” Biochem Biophys Res Commun 335, no. 1 (September 16, 2005): 124–31. https://doi.org/10.1016/j.bbrc.2005.07.071.
       Full Text  Link to Item
    • Osada, Takuya, Michael A. Morse, H Kim Lyerly, and Timothy M. Clay. “Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.” Int Immunol 17, no. 9 (September 2005): 1143–55. https://doi.org/10.1093/intimm/dxh292.
       Full Text  Link to Item
    • Chui, Stephen Y., Timothy M. Clay, H Kim Lyerly, and Michael A. Morse. “The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori.” Cancer Epidemiol Biomarkers Prev 14, no. 8 (August 2005): 1883–89. https://doi.org/10.1158/1055-9965.EPI-04-0775.
       Full Text  Link to Item
    • Kemeny, Nancy, William Jarnagin, Philip Paty, Mithat Gönen, Lawrence Schwartz, Meroë Morse, Gregory Leonard, et al. “Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.” J Clin Oncol 23, no. 22 (August 1, 2005): 4888–96. https://doi.org/10.1200/JCO.2005.07.100.
       Full Text  Link to Item
    • Morse, Michael A. “Adjuvant therapy of colon cancer: current status and future developments.” Clin Colon Rectal Surg 18, no. 3 (August 2005): 224–31. https://doi.org/10.1055/s-2005-916283.
       Full Text  Link to Item
    • Maecker, Holden T., James Moon, Sonny Bhatia, Smita A. Ghanekar, Vernon C. Maino, Janice K. Payne, Kristine Kuus-Reichel, et al. “Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT.” Bmc Immunol 6 (July 18, 2005): 17. https://doi.org/10.1186/1471-2172-6-17.
       Full Text  Link to Item
    • Czito, Brian G., Herbert I. Hurwitz, Robert W. Clough, Douglas S. Tyler, Michael A. Morse, Bryan M. Clary, Theodore N. Pappas, Nishan H. Fernando, and Christopher G. Willett. “Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience.” Int J Radiat Oncol Biol Phys 62, no. 4 (July 15, 2005): 1030–34. https://doi.org/10.1016/j.ijrobp.2004.12.059.
       Full Text  Link to Item
    • Cohn, A., M. A. Morse, B. O’Neil, D. Bellgrau, R. C. Duke, A. J. Franzusoff, S. Munson, J. Ferraro, and T. C. Rodell. “Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: Preliminary safety and immunogenicity results from a phase 1 trial.” J Clin Oncol 23, no. 16_suppl (June 2005): 2571.
       Link to Item
    • Richards, J. M., A. Bedikian, R. Gonzalez, M. B. Atkins, E. Whitman, J. Lutzky, M. A. Morse, et al. “High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial.” J Clin Oncol 23, no. 16_suppl (June 2005): 7543.
       Link to Item
    • Mis, Lydia, Nishan H. Fernando, Hurbert I. Hurwitz, and Michael A. Morse. “Successful desensitization to oxaliplatin.” Ann Pharmacother 39, no. 5 (May 2005): 966–69. https://doi.org/10.1345/aph.1E532.
       Full Text  Link to Item
    • Morse, Michael A., Timothy M. Clay, Amy C. Hobeika, Takuya Osada, Shubi Khan, Stephen Chui, Donna Niedzwiecki, Dennis Panicali, Jeffrey Schlom, and H Kim Lyerly. “Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.” Clin Cancer Res 11, no. 8 (April 15, 2005): 3017–24. https://doi.org/10.1158/1078-0432.CCR-04-2172.
       Full Text  Link to Item
    • Morse, Michael. “Technology evaluation: Rexin-G, Epeius Biotechnologies.” Curr Opin Mol Ther 7, no. 2 (April 2005): 164–69.
       Link to Item
    • White, Rebekah R., H Bill Xie, Marcia R. Gottfried, Brian G. Czito, Herbert I. Hurwitz, Michael A. Morse, Gerald C. Blobe, et al. “Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer.” Ann Surg Oncol 12, no. 3 (March 2005): 214–21. https://doi.org/10.1245/ASO.2005.03.105.
       Full Text  Link to Item
    • Morse, Michael A., Jennifer Garst, Takuya Osada, Shubi Khan, Amy Hobeika, Timothy M. Clay, Nancy Valente, et al. “A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.” J Transl Med 3, no. 1 (February 21, 2005): 9. https://doi.org/10.1186/1479-5876-3-9.
       Full Text  Link to Item
    • Bunce, C., and M. A. Morse. “Editorial overview: What is a vaccine?” Current Opinion in Molecular Therapeutics 7, no. 1 (February 1, 2005): 9–10.
    • Morse, Michael A., Stephen Chui, Amy Hobeika, H Kim Lyerly, and Timothy Clay. “Recent developments in therapeutic cancer vaccines.” Nat Clin Pract Oncol 2, no. 2 (February 2005): 108–13. https://doi.org/10.1038/ncponc0098.
       Full Text  Link to Item
    • Hobeika, Amy C., Michael A. Morse, Takuya Osada, Manar Ghanayem, Donna Niedzwiecki, Robert Barrier, H Kim Lyerly, and Timothy M. Clay. “Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.” J Immunother 28, no. 1 (January 2005): 63–72. https://doi.org/10.1097/00002371-200501000-00008.
       Full Text  Link to Item
    • Mosca, Paul J., Timothy M. Clay, Michael A. Morse, and H Kim Lyerly. “Immune monitoring.” Cancer Treat Res 123 (2005): 369–88. https://doi.org/10.1007/0-387-27545-2_16.
       Full Text  Link to Item
    • Chui, S., T. M. Clay, P. J. Mosca, A. C. Hobeika, T. Osada, L. Galibert, D. Caron, H. K. Lyerly, and M. A. Morse. “Flt3-ligand as a vaccine adjuvant: Results in a study of Flt3-ligand plus tetanus toxoid immunization.” Journal of Applied Research 4, no. 4 (December 1, 2004): 536–49.
    • Morse, M. A., T. M. Clay, A. C. Hobeika, S. Chui, P. J. Mosca, D. Caron, and H. K. Lyerly. “Active immunotherapy with Flt3-ligand mobilized peripheral blood dendritic cells loaded with carcinoembryonic antigen peptide in patients with metastatic malignancies.” Journal of Applied Research 4, no. 4 (December 1, 2004): 554–69.
    • Chui, S. Y., M. A. Morse, T. Doldo, T. Osada, T. M. Clay, H. K. Lyerly, S. Khan, A. Gattis, and A. C. Hobeika. “Regulatory and effector T cell subsets and dendritic cells in breast cancer.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 9697.
       Link to Item
    • Ishioka, G. Y., M. L. Disis, M. A. Morse, C. C. Cunningham, H. J. Lenz, R. A. Figlin, R. W. Chesnut, and J. Fikes. “A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 2525.
       Link to Item
    • Richards, J., A. Y. Bedikian, R. Gonzalez, M. B. Atkins, E. D. Whitman, J. Lutzky, M. A. Morse, T. Amatruda, E. Galanis, and E. Vical Clinical Research Operations Team. “A phase 2 trial of high-dose Allovectin-7 in patients with advanced metastatic melanoma.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 7509.
       Link to Item
    • Gerke, H., R. White, M. F. Byrne, H. Stiffier, R. M. Mitchell, H. I. Hurwitz, M. A. Morse, et al. “Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage.” Dig Liver Dis 36, no. 6 (June 2004): 412–18. https://doi.org/10.1016/s1590-8658(04)00096-9.
       Full Text  Link to Item
    • Czito, Brian G., Timothy J. Hong, Darrel P. Cohen, Douglas S. Tyler, Catherine G. Lee, Mitchell S. Anscher, Kirk A. Ludwig, et al. “A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.” Int J Radiat Oncol Biol Phys 58, no. 3 (March 1, 2004): 779–85. https://doi.org/10.1016/S0360-3016(03)01567-0.
       Full Text  Link to Item
    • Morse, Michael A., H Kim Lyerly, Timothy M. Clay, Omar Abdel-Wahab, Stephen Y. Chui, Jennifer Garst, Jared Gollob, et al. “Immunotherapy of surgical malignancies.” Curr Probl Surg 41, no. 1 (January 2004): 15–132. https://doi.org/10.1016/S0011384003001321.
       Full Text  Link to Item
    • Micames, Carlos, Paul S. Jowell, Rebekah White, Erik Paulson, Rendon Nelson, Michael Morse, Herbert Hurwitz, Theodore Pappas, Douglas Tyler, and Kevin McGrath. “Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA.” Gastrointest Endosc 58, no. 5 (November 2003): 690–95. https://doi.org/10.1016/s0016-5107(03)02009-1.
       Full Text  Link to Item
    • Morse, Michael A., Tim Clay, Kirsten Colling, and H Kim Lyerly. “Preparation of peptide-loaded dendritic cells for cancer immunotherapy.” Mol Biotechnol 25, no. 1 (September 2003): 95–99. https://doi.org/10.1385/MB:25:1:95.
       Full Text  Link to Item
    • Fecci, Peter E., Duane A. Mitchell, Gary E. Archer, Michael A. Morse, H Kim Lyerly, Darell D. Bigner, and John H. Sampson. “The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.” J Neurooncol 64, no. 1–2 (August 2003): 161–76. https://doi.org/10.1007/BF02700031.
       Full Text  Link to Item
    • Califf, Robert M., Michael A. Morse, Janet Wittes, Steven N. Goodman, Daniel K. Nelson, David L. DeMets, R Peter Iafrate, and Jeremy Sugarman. “Toward protecting the safety of participants in clinical trials.” Control Clin Trials 24, no. 3 (June 2003): 256–71. https://doi.org/10.1016/s0197-2456(03)00005-9.
       Full Text  Link to Item
    • Morse, Michael A., Smita K. Nair, Paul J. Mosca, Amy C. Hobeika, Timothy M. Clay, Yuping Deng, David Boczkowski, et al. “Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.” Cancer Invest 21, no. 3 (June 2003): 341–49. https://doi.org/10.1081/cnv-120018224.
       Full Text  Link to Item
    • Onaitis, Mark, Michael Morse, Herbert Hurwitz, Peggy Cotton, Douglas Tyler, Pierre Clavien, and Bryan Clary. “Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases.” Ann Surg 237, no. 6 (June 2003): 782–88. https://doi.org/10.1097/01.SLA.0000071561.76384.19.
       Full Text  Link to Item
    • Heneghan, Michael A., J Elizabeth Tuttle-Newhall, Paul V. Suhocki, Andrew J. Muir, Michael Morse, Jeffrey D. Bornstein, Pamela B. Sylvestre, Bradley Collins, Paul C. Kuo, and Don C. Rockey. “De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant.” Am J Transplant 3, no. 5 (May 2003): 634–38. https://doi.org/10.1034/j.1600-6143.2003.00110.x.
       Full Text  Link to Item
    • Mosca, Paul J., Timothy M. Clay, H. Kim Lyerly, and Michael A. Morse. “Current status of dendritic cell immunotherapy of malignancies.” Int Rev Immunol 22, no. 3–4 (May 2003): 255–81. https://doi.org/10.1080/08830180305223.
       Full Text  Link to Item
    • Bunce, C. J., and M. A. Morse. “Editorial overview - A need for effective adjuvants.” Current Opinion in Molecular Therapeutics 5, no. 1 (February 1, 2003): 8–9.
       Link to Item
    • Bunce, Campbell J., and Michael A. Morse. “A need for effective adjuvants.” Curr Opin Mol Ther 5, no. 1 (February 2003): 8–9.
       Link to Item
    • Morse, Michael A., Timothy M. Clay, Kirsten Colling, Amy Hobeika, Ken Grabstein, Martin A. Cheever, and H Kim Lyerly. “HER2 dendritic cell vaccines.” Clin Breast Cancer 3 Suppl 4 (February 2003): S164–72. https://doi.org/10.3816/cbc.2003.s.007.
       Full Text  Link to Item
    • Mosca, Paul J., H Kim Lyerly, C Denise Ching, Amy C. Hobeika, Timothy M. Clay, and Michael A. Morse. “Proteomics for monitoring immune responses to cancer vaccines.” Curr Opin Mol Ther 5, no. 1 (February 2003): 39–43.
       Link to Item
    • Morse, Michael A., Steve Chui, Timothy M. Clay, and H Kim Lyerly. “Recent areas of development for dendritic cell vaccines.” Cancer Chemother Biol Response Modif 21 (2003): 339–50. https://doi.org/10.1016/s0921-4410(03)21017-6.
       Full Text  Link to Item
    • Chui, S. Y., and M. A. Morse. “Vaccines and gene therapy for colorectal cancer.” Seminars in Colon and Rectal Surgery 13, no. 4 (December 1, 2002): 277–92. https://doi.org/10.1053/scrs.2002.127402.
       Full Text
    • Morse, M. A., P. J. Mosca, T. M. Clay, and H. K. Lyerly. “Dendritic cell-based vaccines in cancer: Clinical experience to date.” American Journal of Cancer 1, no. 5 (December 1, 2002): 313–22. https://doi.org/10.2165/00024669-200201050-00002.
       Full Text
    • Morse, Michael A., Timothy M. Clay, Paul Mosca, and H Kim Lyerly. “Immunoregulatory T cells in cancer immunotherapy.” Expert Opin Biol Ther 2, no. 8 (December 2002): 827–34. https://doi.org/10.1517/14712598.2.8.827.
       Full Text  Link to Item
    • Morse, Michael A. “38th Annual Meeting of the American Society of Clinical Oncology. 18-21 May 2002, Orlando, Florida, USA.” Expert Opin Emerg Drugs 7, no. 2 (October 2002): 335–38. https://doi.org/10.1517/14728214.7.2.335.
       Full Text  Link to Item
    • Mosca, Paul J., Amy C. Hobeika, Kirsten Colling, Timothy M. Clay, Elaine K. Thomas, Dania Caron, H Kim Lyerly, and Michael A. Morse. “Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand.” J Leukoc Biol 72, no. 3 (September 2002): 546–53.
       Link to Item
    • Morse, Michael A., David Rizzieri, Timothy T. Stenzel, Amy C. Hobeika, James J. Vredenburgh, Nelson J. Chao, Timothy M. Clay, Paul J. Mosca, and H Kim Lyerly. “Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.” J Hematother Stem Cell Res 11, no. 4 (August 2002): 659–68. https://doi.org/10.1089/15258160260194802.
       Full Text  Link to Item
    • Morse, Michael A., and H Kim Lyerly. “DNA and RNA modified dendritic cell vaccines.” World J Surg 26, no. 7 (July 2002): 819–25. https://doi.org/10.1007/s00268-002-4058-0.
       Full Text  Link to Item
    • Bunce, C. J., and M. A. Morse. “Editorial overview: Priming, boosting, measuring.” Current Opinion in Molecular Therapeutics 4, no. 1 (June 27, 2002): 13–14.
    • Gasparetto, Cristina, Maura Gasparetto, Michael Morse, Barbara Rooney, James J. Vredenburgh, Gwynn D. Long, David A. Rizzieri, Jennifer Loftis, Nelson J. Chao, and Clay Smith. “Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF.” Cytokine 18, no. 1 (April 7, 2002): 8–19. https://doi.org/10.1006/cyto.2002.1009.
       Full Text  Link to Item
    • Clavien, Pierre-Alain, Nazia Selzner, Michael Morse, Markus Selzner, and Eric Paulson. “Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy.” Surgery 131, no. 4 (April 2002): 433–42. https://doi.org/10.1067/msy.2002.122374.
       Full Text  Link to Item
    • Clay, Timothy M., Michael Morse, and H Kim Lyerly. “Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes.” Expert Opin Biol Ther 2, no. 4 (April 2002): 353–60. https://doi.org/10.1517/14712598.2.4.353.
       Full Text  Link to Item
    • Nair, Smita K., Michael Morse, David Boczkowski, R Ian Cumming, Ljiljana Vasovic, Eli Gilboa, and H Kim Lyerly. “Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.” Ann Surg 235, no. 4 (April 2002): 540–49. https://doi.org/10.1097/00000658-200204000-00013.
       Full Text  Link to Item
    • Morse, Michael A., Timothy M. Clay, and H Kim Lyerly. “Current status of adoptive immunotherapy of malignancies.” Expert Opin Biol Ther 2, no. 3 (March 2002): 237–47. https://doi.org/10.1517/14712598.2.3.237.
       Full Text  Link to Item
    • Bunce, Campbell J., and Michael A. Morse. “Priming, boosting, measuring.” Curr Opin Mol Ther 4, no. 1 (February 2002): 13–14.
       Link to Item
    • Clavien, Pierre-Alain, Koo Jeong Kang, Nazia Selzner, Michael A. Morse, and Paul V. Suhocki. “Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosis.” J Gastrointest Surg 6, no. 1 (January 2002): 95–101. https://doi.org/10.1016/s1091-255x(01)00037-3.
       Full Text  Link to Item
    • Morse, Michael A., Paul J. Mosca, Timothy M. Clay, and H Kim Lyerly. “Dendritic cell maturation in active immunotherapy strategies.” Expert Opin Biol Ther 2, no. 1 (January 2002): 35–43. https://doi.org/10.1517/14712598.2.1.35.
       Full Text  Link to Item
    • Morse, Michael A., Smita K. Nair, David Boczkowski, Douglas Tyler, Herbert I. Hurwitz, Alan Proia, Timothy M. Clay, Jeffrey Schlom, Eli Gilboa, and H Kim Lyerly. “The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.” Int J Gastrointest Cancer 32, no. 1 (2002): 1–6. https://doi.org/10.1385/IJGC:32:1:1.
       Full Text  Link to Item
    • Morse, Michael A., Timothy M. Clay, and H Kim Lyerly. “CEA loaded dendritic cell vaccines.” Cancer Chemother Biol Response Modif 20 (2002): 385–90.
       Link to Item
    • Morse, M. A. “Technology evaluation: ISIS-2503, Isis Pharmaceuticals.” Curr Opin Mol Ther 3, no. 6 (December 2001): 589–94.
       Link to Item
    • Onaitis, M. W., R. B. Noone, R. Fields, H. Hurwitz, M. Morse, P. Jowell, K. McGrath, et al. “Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival.” Ann Surg Oncol 8, no. 10 (December 2001): 801–6. https://doi.org/10.1007/s10434-001-0801-2.
       Full Text  Link to Item
    • White, R. R., H. I. Hurwitz, M. A. Morse, C. Lee, M. S. Anscher, E. K. Paulson, M. R. Gottfried, et al. “Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.” Ann Surg Oncol 8, no. 10 (December 2001): 758–65. https://doi.org/10.1007/s10434-001-0758-1.
       Full Text  Link to Item
    • White, R. R., E. K. Paulson, K. S. Freed, M. T. Keogan, H. I. Hurwitz, C. Lee, M. A. Morse, et al. “Staging of pancreatic cancer before and after neoadjuvant chemoradiation.” J Gastrointest Surg 5, no. 6 (November 2001): 626–33. https://doi.org/10.1016/s1091-255x(01)80105-0.
       Full Text  Link to Item
    • Morse, M. A. “The role of glutathione S-transferase P1-1 in colorectal cancer: friend or foe?” Gastroenterology 121, no. 4 (October 2001): 1010–13. https://doi.org/10.1053/gast.2001.28571.
       Full Text  Link to Item
    • Morse, M. A. “Technology evaluation: CEA-TRICOM, Therion Biologics Corp.” Curr Opin Mol Ther 3, no. 4 (August 2001): 407–12.
       Link to Item
    • Morse, M. A. “American Society of Clinical Oncology - 37th Annual Meeting. Novel antitumor agents. 12-15 May 2001, San Francisco, CA, USA.” Idrugs 4, no. 8 (August 2001): 853–56.
       Link to Item
    • Morse, M. A. “American Society of Clinical Oncology - 37th Annual Meeting. Small molecule tyrosine kinase inhibitors. 12-15 May 2001, San Francisco, CA, USA.” Idrugs 4, no. 8 (August 2001): 857–59.
       Link to Item
    • Tokunaga, K., M. L. Greenberg, M. A. Morse, R. I. Cumming, H. K. Lyerly, and B. R. Cullen. “Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates.” J Virol 75, no. 15 (August 2001): 6776–85. https://doi.org/10.1128/JVI.75.15.6776-6785.2001.
       Full Text  Link to Item
    • Gupta, A., R. Nines, K. A. Rodrigo, R. A. Aziz, P. S. Carlton, D. L. Gray, V. E. Steele, M. A. Morse, and G. D. Stoner. “Effects of dietary N-(4-hydroxyphenyl)retinamide on N-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis in the Fischer 344 rat.” J Natl Cancer Inst 93, no. 13 (July 4, 2001): 990–98. https://doi.org/10.1093/jnci/93.13.990.
       Full Text  Link to Item
    • Burman, W. J., and R. T. Schooley. “The role of local institutional review boards in protecting human research subjects.” Jama 285, no. 21 (June 6, 2001): 2713. https://doi.org/10.1001/jama.285.21.2713.
       Full Text  Link to Item
    • Onaitis, M. W., R. B. Noone, M. Hartwig, H. Hurwitz, M. Morse, P. Jowell, K. McGrath, et al. “Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience.” Ann Surg 233, no. 6 (June 2001): 778–85. https://doi.org/10.1097/00000658-200106000-00007.
       Full Text  Link to Item
    • Clay, T. M., A. C. Hobeika, P. J. Mosca, H. K. Lyerly, and M. A. Morse. “Assays for monitoring cellular immune responses to active immunotherapy of cancer.” Clin Cancer Res 7, no. 5 (May 2001): 1127–35.
       Link to Item
    • Mallery, S. R., A. Shenderova, P. Pei, S. Begum, J. R. Ciminieri, R. F. Wilson, B. C. Casto, D. E. Schuller, and M. A. Morse. “Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model.” Anticancer Res 21, no. 3B (May 2001): 1713–22.
       Link to Item
    • Morse, M. A., R. M. Califf, and J. Sugarman. “Monitoring and ensuring safety during clinical research.” Jama 285, no. 9 (March 7, 2001): 1201–5. https://doi.org/10.1001/jama.285.9.1201.
       Full Text  Link to Item
    • Mosca, P. J., A. C. Hobeika, T. M. Clay, M. A. Morse, and H. K. Lyerly. “Direct detection of cellular immune responses to cancer vaccines.” Surgery 129, no. 3 (March 2001): 248–54. https://doi.org/10.1067/msy.2001.108609.
       Full Text  Link to Item
    • Morse, M. A. “Technology evaluation: BLP-25, Biomira Inc.” Curr Opin Mol Ther 3, no. 1 (February 2001): 102–5.
       Link to Item
    • Morse, M. A. “Technology evaluation: VEGF165 gene therapy, Valentis Inc.” Curr Opin Mol Ther 3, no. 1 (February 2001): 97–101.
       Link to Item
    • Morse, M. A., T. M. Clay, A. C. Hobeika, P. J. Mosca, and H. K. Lyerly. “Monitoring cellular immune responses to cancer immunotherapy.” Curr Opin Mol Ther 3, no. 1 (February 2001): 45–52.
       Link to Item
    • Morse, M. A., and C. Bunce. “Editorial overview - A cornucopia of strategies for the immunotherapy of cancer.” Current Opinion in Molecular Therapeutics 3, no. 1 (February 1, 2001): 13–14.
       Link to Item
    • Selzner, M., A. Bielawska, M. A. Morse, H. A. Rüdiger, D. Sindram, Y. A. Hannun, and P. A. Clavien. “Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer.” Cancer Res 61, no. 3 (February 1, 2001): 1233–40.
       Link to Item
    • Hobeika, A. C., T. M. Clay, P. J. Mosca, H. K. Lyerly, and M. A. Morse. “Quantitating therapeutically relevant T-cell responses to cancer vaccines.” Crit Rev Immunol 21, no. 1–3 (2001): 287–97.
       Link to Item
    • Morse, M. A., and C. Bunce. “A cornucopia of strategies for the immunotherapy of cancer.” Current Opinion in Molecular Therapeutics 3, no. 1 (January 1, 2001): 13–14.
    • Morse, M. A., S. Nair, M. Fernandez-Casal, Y. Deng, M. St Peter, R. Williams, A. Hobeika, et al. “Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer.” J Clin Oncol 18, no. 23 (December 1, 2000): 3883–93. https://doi.org/10.1200/JCO.2000.18.23.3883.
       Full Text  Link to Item
    • Mosca, P. J., A. C. Hobeika, T. M. Clay, S. K. Nair, E. K. Thomas, M. A. Morse, and H. K. Lyerly. “A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment.” Blood 96, no. 10 (November 15, 2000): 3499–3504.
       Link to Item
    • Lyerly, H. K., T. Clay, and M. A. Morse. “Optimizing dendritic cell function by genetic modification.” J Natl Cancer Inst 92, no. 15 (August 2, 2000): 1198–99. https://doi.org/10.1093/jnci/92.15.1198.
       Full Text  Link to Item
    • Morse, M. A. “Technology evaluation: gene therapy (IL-2), Valentis Inc.” Curr Opin Mol Ther 2, no. 4 (August 2000): 448–52.
       Link to Item
    • Morse, M. A. “Technology evaluation: Theratope, Biomira Inc.” Curr Opin Mol Ther 2, no. 4 (August 2000): 453–58.
       Link to Item
    • Morse, M. A. “American Society of Clinical Oncology - 36th Annual Meeting.” Idrugs 3, no. 8 (August 2000): 846–50.
       Link to Item
    • Morse, M. A., E. Bossen, T. A. D’Amico, W. Williamson, and R. Johnson. “Myxoid liposarcoma of the supraclavicular fossa.” Chest 117, no. 5 (May 2000): 1518–20. https://doi.org/10.1378/chest.117.5.1518.
       Full Text  Link to Item
    • Selzner, M., M. A. Morse, J. J. Vredenburgh, W. C. Meyers, and P. A. Clavien. “Liver metastases from breast cancer: long-term survival after curative resection.” Surgery 127, no. 4 (April 2000): 383–89. https://doi.org/10.1067/msy.2000.103883.
       Full Text  Link to Item
    • Bunce, C., and M. A. Morse. “On the road to effective vaccine development.” Current Opinion in Molecular Therapeutics 2, no. 1 (March 21, 2000): 18–19.
    • Morse, M. A. “Stem cell therapy (Aastrom Biosciences Inc).” Idrugs 3, no. 3 (March 2000): 346–53.
       Link to Item
    • Morse, M. A., and H. K. Lyerly. “Clinical applications of dendritic cell vaccines.” Curr Opin Mol Ther 2, no. 1 (February 2000): 20–28.
       Link to Item
    • Mosca, P. J., M. A. Morse, T. A. D’Amico, J. Crawford, and H. K. Lyerly. “Gene therapy for lung cancer.” Clin Lung Cancer 1, no. 3 (February 2000): 218–26. https://doi.org/10.3816/clc.2000.n.005.
       Full Text  Link to Item
    • Morse, M. A. “Theratope Biomira Inc.” Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs 2, no. 4 (January 1, 2000): 405–13.
    • Morse, M. A., and H. K. Lyerly. “Dendritic cell-based immunization for cancer therapy.” Adv Exp Med Biol 465 (2000): 335–46. https://doi.org/10.1007/0-306-46817-4_28.
       Full Text  Link to Item
    • Morse, M. A. “Technology evaluation: Stem-cell therapy, Aastrom Biosciences Inc.” Curr Opin Mol Ther 1, no. 6 (December 1999): 745–52.
       Link to Item
    • Morse, M. A., J. J. Vredenburgh, and H. K. Lyerly. “A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.” J Hematother Stem Cell Res 8, no. 6 (December 1999): 577–84. https://doi.org/10.1089/152581699319731.
       Full Text  Link to Item
    • Morse, M. A., H. K. Lyerly, and Y. Li. “The role of IL-13 in the generation of dendritic cells in vitro.” J Immunother 22, no. 6 (November 1999): 506–13. https://doi.org/10.1097/00002371-199911000-00005.
       Full Text  Link to Item
    • Clavien, P. A., M. Selzner, and M. A. Morse. “Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor.” Ann Surg 230, no. 4 (October 1999): 607–10. https://doi.org/10.1097/00000658-199910000-00016.
       Full Text  Link to Item
    • Selzner, M., M. A. Morse, D. Sindram, A. Bielawska, Y. A. Hannun, and P. A. Clavien. “Ceramide analogue B13 induces apoptosis and completely inhibits growth of liver metastases from colon cancer in vivo a new strategy for the treatment of metastatic liver disease.” Hepatology 30, no. 4 (October 1, 1999): 161A-161A.
       Link to Item
    • Lyerly, H. K., and M. A. Morse. “Carcinoembryonic antigen peptide-pulsed dendritic cells in patients with metastatic cancer.” Clin Lung Cancer 1, no. 1 (August 1999): 70–72. https://doi.org/10.3816/clc.1999.n.005.
       Full Text  Link to Item
    • Nair, S. K., S. Hull, D. Coleman, E. Gilboa, H. K. Lyerly, and M. A. Morse. “Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA.” Int J Cancer 82, no. 1 (July 2, 1999): 121–24. https://doi.org/10.1002/(sici)1097-0215(19990702)82:1<121::aid-ijc20>3.0.co;2-x.
       Full Text  Link to Item
    • Morse, M. A., Y. Deng, D. Coleman, S. Hull, E. Kitrell-Fisher, S. Nair, J. Schlom, M. E. Ryback, and H. K. Lyerly. “A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.” Clin Cancer Res 5, no. 6 (June 1999): 1331–38.
       Link to Item
    • Morse, M. A., and H. K. Lyerly. “Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials.” Ann Surg Oncol 6, no. 2 (March 1999): 218–23. https://doi.org/10.1007/s10434-999-0218-x.
       Full Text  Link to Item
    • Morse, M. A., R. E. Coleman, G. Akabani, N. Niehaus, D. Coleman, and H. K. Lyerly. “Migration of human dendritic cells after injection in patients with metastatic malignancies.” Cancer Res 59, no. 1 (January 1, 1999): 56–58.
       Link to Item
    • Morse, M. A., and H. K. Lyerly. “Dendritic cell-based approaches to cancer immunotherapy.” Expert Opin Investig Drugs 7, no. 10 (October 1998): 1617–27. https://doi.org/10.1517/13543784.7.10.1617.
       Full Text  Link to Item
    • Morse, M. A., H. K. Lyerly, E. Gilboa, E. Thomas, and S. K. Nair. “Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells.” Cancer Res 58, no. 14 (July 15, 1998): 2965–68.
       Link to Item
    • Miralles, G. D., C. A. Smith, L. P. Whichard, M. A. Morse, B. F. Haynes, and D. D. Patel. “CD34+CD38-lin- cord blood cells develop into dendritic cells in human thymic stromal monolayers and thymic nodules.” J Immunol 160, no. 7 (April 1, 1998): 3290–98.
       Link to Item
    • Nair, S. K., D. Boczkowski, M. Morse, R. I. Cumming, H. K. Lyerly, and E. Gilboa. “Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.” Nat Biotechnol 16, no. 4 (April 1998): 364–69. https://doi.org/10.1038/nbt0498-364.
       Full Text  Link to Item
    • Morse, M. A., and H. K. Lyerly. “Immunotherapy of cancer using dendritic cells.” Cytokines Cell Mol Ther 4, no. 1 (March 1998): 35–44.
       Link to Item
    • Wong, C., M. Morse, and S. K. Nair. “Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides.” J Immunother 21, no. 1 (January 1998): 32–40. https://doi.org/10.1097/00002371-199801000-00004.
       Full Text  Link to Item
    • Miralles, G. D., D. D. Patel, M. FernandezCasal, L. P. Whichard, M. A. Morse, and C. A. Smith. “Extrathymic stem cells develop into dendritic cells in human thymic microenvironments in vitro.” Blood 90, no. 10 (November 15, 1997): 3382–3382.
       Link to Item
    • Morse, M. A., L. J. Zhou, T. F. Tedder, H. K. Lyerly, and C. Smith. “Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy.” Ann Surg 226, no. 1 (July 1997): 6–16. https://doi.org/10.1097/00000658-199707000-00002.
       Full Text  Link to Item
    • Clary, B. M., E. C. Coveney, R. Philip, D. G. Blazer, M. Morse, E. Gilboa, and H. K. Lyerly. “Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.” Cancer Gene Ther 4, no. 2 (March 1997): 97–104.
       Link to Item
    • Clary, B. M., E. C. Coveney, D. G. Blazer, R. Philip, M. Philip, M. Morse, E. Gilboa, and H. K. Lyerly. “Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system.” J Immunother 20, no. 1 (January 1997): 26–37. https://doi.org/10.1097/00002371-199701000-00003.
       Full Text  Link to Item
    • Morse, M. A., and D. L. Rutlen. “Influence of nitroglycerin on splanchnic capacity and splanchnic capacity-cardiac output relationship.” J Appl Physiol (1985) 76, no. 1 (January 1994): 112–19. https://doi.org/10.1152/jappl.1994.76.1.112.
       Full Text  Link to Item
    • Morse, M. A., L. Bell, and D. L. Rutlen. “Influence of splanchnic intravascular volume changes on cardiac output during muscarinic receptor stimulation in the anaesthetized dog.” Acta Physiol Scand 138, no. 3 (March 1990): 331–36. https://doi.org/10.1111/j.1748-1716.1990.tb08854.x.
       Full Text  Link to Item

  • Book Sections

    • Doan, P. L., J. N. Vauthey, M. Palavecino, and M. A. Morse. “Colorectal Liver Metastases.” In Malignant Liver Tumors: Current and Emerging Therapies: Third Edition, 342–46, 2009. https://doi.org/10.1002/9781444317053.ch29.
       Full Text
    • Huitzil-Melendez, F. D., G. K. Abou-Alfa, and M. A. Morse. “Novel Therapies Targeted at Signal Transduction in Liver Tumors.” In Malignant Liver Tumors: Current and Emerging Therapies: Third Edition, 382–92, 2009. https://doi.org/10.1002/9781444317053.ch32.
       Full Text
    • Samaras, P., M. A. Morse, and B. C. Pestalozzi. “Systemic Treatment of Hepatobiliary Tumors.” In Malignant Liver Tumors: Current and Emerging Therapies: Third Edition, 107–21, 2009. https://doi.org/10.1002/9781444317053.ch10.
       Full Text
    • Hsu, D. S., M. Morse, T. Clay, G. Devi, and H. Kim Lyerly. “Immune Cells and the Tumor Microenvironment.” In Genomic and Personalized Medicine, Two-Vol Set, 818–29, 2009. https://doi.org/10.1016/B978-0-12-369420-1.00068-8.
       Full Text
    • Morse, M. A., T. M. Clay, and H. K. Lyerly. “Tumor antigens.” In General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology, 17–31, 2008. https://doi.org/10.1007/978-1-4020-6087-8_2.
       Full Text
    • Morse, M. “Foreword,” Vol. 8, 2008.
    • Hobeika, A. C., M. A. Morse, T. M. Clay, T. Osada, P. J. Mosca, and H. K. Lyerly. “Intracellular Cytokine Assays.” In Measuring Immunity: Basic Biology and Clinical Assessment, 336–40, 2005. https://doi.org/10.1016/B978-012455900-4/50290-7.
       Full Text

  • Other Articles

    • Hamilton, E., K. Blackwell, A. C. Hobeika, T. M. Clay, G. Broadwater, X. R. Ren, W. Chen, et al. “Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion.” J Transl Med, 2013. https://doi.org/10.1186/1479-5876-11-82.
       Full Text  Link to Item
    • Hobeika, A. C., T. M. Clay, and M. A. Morse. “Monitoring immunity to cancer vaccines.” Enhancer  Biotherapy of Cancer, December 4, 2006.
    • Morse, M. A., H. K. Lyerly, and T. M. Clay. “Immunotherapy of surgical malignancies: Commentary.” Diseases of the Colon and Rectum, January 1, 2005.
    • Morse, M., B. Clary, and H. Kim Lyerly. “Establishment of a nude mouse model of hepatic metastasis for evaluation of targeted retroviral gene delivery: Commentary.” Journal of Surgical Oncology, February 1, 2003. https://doi.org/10.1002/jso.10169.
       Full Text
    • Lyerly, H. K., M. A. Morse, and T. M. Clay. “Surrogate markers of effective anti-tumor immunity.” Ann Surg Oncol, April 2001. https://doi.org/10.1007/s10434-001-0190-6.
       Full Text  Link to Item
    • Morse, M. A., T. M. Clay, A. C. Hobeika, P. J. Mosca, and H. K. Lyerly. “Surrogate markers of response to cancer immunotherapy.” Expert Opin Biol Ther, March 2001. https://doi.org/10.1517/14712598.1.2.153.
       Full Text  Link to Item

  • Conference Papers

    • Thorpe, Matthew P., Ari Kane, Jason Zhu, Michael A. Morse, Terence Wong, and Salvador Borges-Neto. “Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.” In The Journal of Clinical Endocrinology and Metabolism, Vol. 105, 2020. https://doi.org/10.1210/clinem/dgz074.
       Full Text
    • Kaneko, Kensuke, Takuya Osada, Philip F. Hughes, Timothy A. Haystead, Michael A. Morse, and Herbert K. Lyerly. “Abstract 3731: A novel heat shock protein 90-targeted photosensitizer (HS-201) enables enhanced tumor-specific photodynamic therapy of inflammatory breast cancers.” In Tumor Biology. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.am2019-3731.
       Full Text
    • Liu, Seiya Y., Sant P. Chawla, Howard Bruckner, Michael A. Morse, Noah Federman, Jorge G. Ignacio, Filomena San Juan, Roseo A. Manalo, Frederick L. Hall, and Erlinda Maria Gordon. “Reporting Long Term Survival Following Precision Tumor-Targeted Gene Delivery to Advanced Chemotherapy-Resistant Malignancies: An Academic Milestone.” In Molecular Therapy, 27:133–133. CELL PRESS, 2019.
       Link to Item
    • Crosby, E. J., W. R. Gwin, S. Chang, H. T. Maecker, V. Lubkov, J. C. Snyder, G. Broadwater, et al. “Abstract P2-09-16: CD8 T cells induced by novel alphaviral vector predict improved progression free survival in advanced HER2+ breast cancer patients.” In Poster Session Abstracts. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.sabcs18-p2-09-16.
       Full Text
    • Rosenberg, J. E., P. Sharma, F. G. M. de Braud, U. Basso, E. Calvo, P. Bono, M. Morse, et al. “Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032.” In Ann Oncol, 29 Suppl 8:viii725, 2018. https://doi.org/10.1093/annonc/mdy424.038.
       Full Text  Link to Item
    • Kopetz, Scott, Vittorina Zagonel, Michael J. Overman, Ray McDermott, Michael A. Morse, Franklin L. Chen, James Lee, et al. “Microbiome analyses in patients with previously treated, deficient DNA mismatch repair/microsatellite instability-high metastatic colorectal cancer treated with nivolumab +/- ipilimumab: CheckMate 142.” In Journal for Immunotherapy of Cancer, Vol. 5. BMC, 2017.
       Link to Item
    • Lonardi, S., T. Andre, K. Y. M. Wong, M. Morse, R. McDermott, A. Hill, A. Hendlisz, et al. “Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study.” In Ann Oncol, 28 Suppl 6:vi3, 2017. https://doi.org/10.1093/annonc/mdx422.001.
       Full Text  Link to Item
    • Kaneko, Kensuke, Takuya Osada, Timothy A. Haystead, Michael A. Morse, and Herbert K. Lyerly. “Abstract 4709: Induction of enhanced tumor-specific immunity by Hsp90 targeted photodynamic therapy (Hsp90-PDT) combined with immune checkpoint inhibition.” In Immunology. American Association for Cancer Research, 2017. https://doi.org/10.1158/1538-7445.am2017-4709.
       Full Text
    • Devi, Gayathri R., Eun-Sil Shelley Hwang, John Stewart, Michael A. Morse, and Steven Van Laere. “Abstract B44: Immune pathway dysregulations in inflammatory breast cancer health disparity.” In Cell, Molecular, and Tumor Biology. American Association for Cancer Research, 2017. https://doi.org/10.1158/1538-7755.disp16-b44.
       Full Text
    • Overman, Michael J., Sara Lonardi, Francesco Leone, Raymond S. McDermott, Michael A. Morse, Ka Yeung Mark Wong, Bart Neyns, et al. “Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.” In Journal of Clinical Oncology, 35:519–519. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.4_suppl.519.
       Full Text
    • Overman, M. J., S. Kopetz, S. Lonardi, R. McDermott, F. Leone, J. Leach, H. J. Lenz, et al. “Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study.” In Annals of Oncology, 27:vi158, 2016. https://doi.org/10.1093/annonc/mdw370.27.
       Full Text
    • Rosenberg, J. E., P. Bono, J. Kim, P. Spiliopoulou, E. Calvo, R. Pillai, P. A. Ott, et al. “Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study.” In Annals of Oncology, 27:vi271, 2016. https://doi.org/10.1093/annonc/mdw373.12.
       Full Text
    • Overman, Michael J., Scott Kopetz, Raymond S. McDermott, Joseph Leach, Sara Lonardi, Heinz-Josef Lenz, Michael A. Morse, et al. “Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.” In Journal of Clinical Oncology, 34:3501–3501. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.3501.
       Full Text
    • Sharma, Padmanee, Petri Bono, Joseph W. Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi Narayana Pillai, Patrick Alexander Ott, et al. “Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.” In Journal of Clinical Oncology, 34:4501–4501. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.4501.
       Full Text
    • Clark, Joseph, Michael A. Morse, Michael K. K. Wong, David F. McDermott, Howard Kaufman, Gregory A. Daniels, Jessica C. Perritt, Hong Hua, and Sandra Aung. “Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).” In Journal of Clinical Oncology, 34:511–511. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.511.
       Full Text
    • Clark, Joseph I., Michael A. Morse, Michael K. K. Wong, David F. Mcdermott, Howard L. Kaufman, Gregory A. Daniels, Jessica C. Perritt, Hong Hua, and Sandra Aung. “Durability of responses in patients with metastatic renal cell carcinoma treated with high dose lnterleukin-2 (HD IL-2).” In Bju International, 116:6–6. WILEY-BLACKWELL, 2015.
       Link to Item
    • Antonia, S. J., J. Bendell, M. Taylor, E. Calvo, D. Jaeger, F. de Braud, P. A. Ott, et al. “Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.” In Annals of Oncology, 26:74–75. OXFORD UNIV PRESS, 2015.
       Link to Item
    • Calvo, E., J. A. López-Martin, J. Bendell, J. P. Eder, M. Taylor, P. A. Ott, M. C. Pietanza, et al. “3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC).” In European Journal of Cancer, 51:S633–S633. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(16)31739-7.
       Full Text
    • Aung, Sandra, Michael A. Morse, Michael K. K. Wong, Howard Kaufman, Gregory A. Daniels, and David F. McDermott. “High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).” In Journal of Clinical Oncology, 33:423–423. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.7_suppl.423.
       Full Text
    • Duffy, Austin G., Muhammad Shaalan Beg, Tim F. Greten, Melony A. Beatson, Sharon Mavroukakis, Sandip Pravin Patel, Michael A. Morse, and Philip M. Arlen. “A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinox (F).” In Journal of Clinical Oncology, 33:TPS499–TPS499. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.tps499.
       Full Text
    • Clark, Joseph I., Michael K. Wong, Gregory A. Daniels, Howard L. Kaufman, David F. McDermott, Michael A. Morse, and Sandra Aung. “Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era.” In Bju International, 114:5–5. WILEY-BLACKWELL, 2014.
       Link to Item
    • Gabitzsch, Elizabeth Susan, Michael A. Morse, H Kim Lyerly, Joseph Balint, and Frank Jones. “Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011.” In Journal of Clinical Oncology, 32:3093–3093. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.3093.
       Full Text
    • Holcombe, Randall F., Joanne Xiu, Zoran Gatalica, and Michael A. Morse. “Molecular profiling of bile duct and gallbladder cancer to identify different therapeutic options.” In Journal of Clinical Oncology, 32:4097–4097. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.4097.
       Full Text
    • Gabitzsch, Elizabeth S., Michael A. Morse, H Kim Lyerly, and Frank Jones. “Abstract LB-164: Treatment of advanced stage colorectal cancer with ETBX-011 immunotherapeutic.” In Clinical Trials. American Association for Cancer Research, 2013. https://doi.org/10.1158/1538-7445.am2013-lb-164.
       Full Text
    • Patel, Sandip P., Michael A. Morse, Luiz A. Diaz, Nilofer S. Azad, Sherri Haley, and Phil M. Arlen. “Abstract LB-161: A phase I safety study of NPC-1C, a novel, therapeutic antibody to treat pancreas and colorectal cancers.” In Clinical Trials. American Association for Cancer Research, 2013. https://doi.org/10.1158/1538-7445.am2013-lb-161.
       Full Text
    • Smith, Alastair D., Andrew J. Muir, Michael A. Morse, Paul V. Suhocki, and Kadiyala V. Ravindra. “Liver Transplantation Following Down-Staging of a Large Primary Liver Tumor Associated with a Very High Serum Alpha Fetoprotein Concentration.” In Liver Transplantation, 17:S275–76. WILEY-BLACKWELL, 2011.
       Link to Item
    • Bullock, K. E., H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
       Link to Item
    • Clay, T. M., A. Hobeika, T. Osada, D. Serra, D. Niedzwiecki, H. K. Lyerly, and M. A. Morse. “Depletion of human regulatory T cells (Treg) and antigen-specific immune responses to cancer vaccines.” In Journal of Clinical Oncology, Vol. 26, 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.3010.
       Full Text  Link to Item
    • Uronis, H. E., J. E. Herndon, A. Coan, K. Bronson, J. Wheeler, H. K. Lyerly, M. A. Morse, and A. P. Abernethy. “E/Tablets to collect research-quality, patient-reported data.” In Journal of Clinical Oncology, 26:17528–17528. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.17528.
       Full Text
    • Nelson, J. W., C. G. Willett, R. Clough, B. M. Clary, T. N. Pappas, D. S. Tyler, J. C. Bendell, H. I. Hurwitz, M. A. Morse, and B. G. Czito. “Concurrent Chemoradiation for Resectable Extrahepatic Cholangiocarcinoma.” In International Journal of Radiation Oncology*Biology*Physics, 69:S303–S303. Elsevier BV, 2007. https://doi.org/10.1016/j.ijrobp.2007.07.1354.
       Full Text
    • Hsu, S. D., C. K. Anders, C. R. Acharya, Y. Zhang, Y. Wang, J. A. Foekens, K. L. Blackwell, C. G. Drake, M. A. Morse, and P. G. Febbo. “Immune signatures hold prognostic import across solids tumors.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
       Link to Item
    • Speca, J. C., A. L. Mears, P. A. Creel, S. E. Yenser, J. C. Bendell, M. A. Morse, H. I. Hurwitz, A. J. Armstrong, and D. J. George. “Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
       Link to Item
    • Nelson, J. W., C. R. Kelsey, C. G. Willett, D. S. Tyler, T. N. Pappas, H. I. Hurwitz, J. C. Bendell, M. A. Morse, R. Clough, and B. G. Czito. “2136.” In International Journal of Radiation Oncology*Biology*Physics, 66:S286–S286. Elsevier BV, 2006. https://doi.org/10.1016/j.ijrobp.2006.07.540.
       Full Text
    • Fisher, Deborah A., Christopher R. Mantyh, Michael A. Morse, Richard G. Prosnitz, Gregory R. Samsa, and Meenal B. Patwardhan. “Quality measures for colorectal cancer diagnosis: A systematic review.” In Gastroenterology, 130:A616–A616. W B SAUNDERS CO-ELSEVIER INC, 2006.
       Link to Item
    • Osada, Takuya, Heather Labreche, Zachery C. Hartman, Delila Serra, Michael A. Morse, H Kim Lyerly, Andrea Amalfitano, and Timothy M. Clay. “Replication-competent packaging-deficient [E1+, 100k-] adenoviral vector-transduced dendritic cells can efficiently induce antigen-specific immune responses.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.
       Link to Item
    • Woo, Christopher Y., Takuya Osada, Xiao Yi Yang, Gangjun Lei, Matthew McKinney, Heather Labreche, Zachary C. Hartman, et al. “Induction of Wilms' tumor protein (WT1)-specific immunity using a WT1-expressing adenovirus vaccine.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.
       Link to Item
    • Cohn, A., M. A. Morse, B. O’Neil, D. Bellgrau, R. C. Duke, A. J. Franzusoff, S. Munson, J. Ferraro, and T. C. Rodell. “Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: Preliminary safety and immunogenicity results from a phase 1 trial.” In Journal of Clinical Oncology, 23:183S-183S. AMER SOC CLINICAL ONCOLOGY, 2005.
       Link to Item
    • Richards, J. M., A. Bedikian, R. Gonzalez, M. B. Atkins, E. Whitman, J. Lutzky, M. A. Morse, T. Amatruda, E. Galanis, and J. Thompson. “High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial.” In Journal of Clinical Oncology, 23:720S-720S. AMER SOC CLINICAL ONCOLOGY, 2005.
       Link to Item
    • Chui, S. Y., M. A. Morse, T. Doldo, T. Osada, T. M. Clay, H. K. Lyerly, S. Khan, A. Gattis, and A. C. Hobeika. “Regulatory and effector T cell subsets and dendritic cells in breast cancer.” In Journal of Clinical Oncology, 22:884S-884S. AMER SOC CLINICAL ONCOLOGY, 2004.
       Link to Item
    • Ishioka, G. Y., M. L. Disis, M. A. Morse, C. C. Cunningham, H. J. Lenz, R. A. Figlin, R. W. Chesnut, and J. Fikes. “A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients.” In Journal of Clinical Oncology, 22:169S-169S. AMER SOC CLINICAL ONCOLOGY, 2004.
       Link to Item
    • Richards, J., A. Y. Bedikian, R. Gonzalez, M. B. Atkins, E. D. Whitman, J. Lutzky, M. A. Morse, T. Amatruda, and E. Galanis. “A phase 2 trial of high-dose allovectin-7 in patients with advanced metastatic melanoma.” In Journal of Clinical Oncology, 22:712S-712S. AMER SOC CLINICAL ONCOLOGY, 2004.
       Link to Item
    • Cheng, T. Y., R. White, T. Ueno, H. I. Hurwitz, M. A. Morse, B. Czito, B. M. Clary, T. N. Pappas, and D. S. Tyler. “Effects of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy.” In Annals of Surgical Oncology, 11:S54–55. Springer Science and Business Media LLC, 2004. https://doi.org/10.1007/bf02523980.
       Full Text
    • Osada, T., M. A. Morse, T. M. Clay, A. Shimosaka, and H. K. Lyerly. “Suppression of antigen-specific CTL generation by human NKT cell secretion of TH2 cytokines.” In Faseb Journal, 17:C77–78. FEDERATION AMER SOC EXP BIOL, 2003.
       Link to Item
    • Venturi, C. B., T. Osada, D. Serraz, Z. Hartman, C. Evelyn, M. A. Morse, T. M. Clay, A. Amalfitano, and H. K. Lyerly. “Comparison of antigen-specific T cell responses induced by transduction of human dendritic cells with E1- and E1-, E2b- adenoviral vectors: Development of adenovirus vectors for DC-based anti-tumor immunotherapy.” In Faseb Journal, 17:C331–C331. FEDERATION AMER SOC EXP BIOL, 2003.
       Link to Item
    • White, R., H. B. Xie, M. R. Gottfried, B. G. Czito, H. I. Hurwitz, M. A. Morse, E. K. Paulson, et al. “Prognostic significance of histologic response to preoperative chemoradiation for periampullary tumors.” In Annals of Surgical Oncology, 10:S62–S62. LIPPINCOTT WILLIAMS & WILKINS, 2003.
       Link to Item
    • Colling, K. L., A. C. Hobeika, P. J. Mosca, T. M. Clay, H. K. Lyerly, and M. A. Morse. “Enumerating functionally mature monocyte-derived dendritic cells for use in cancer immunotherapy.” In Blood, 98:851A-851A. AMER SOC HEMATOLOGY, 2001.
       Link to Item
    • Hobeika, A. C., S. Peplinski, M. A. Morse, P. J. Mosca, T. C. Clay, and H. K. Lyerly. “Quantitating antigen specific T cell responses in peripheral blood: A comparison of peptide MHC tetramer, ELISpot and intracellular cytokine analysis.” In Blood, 98:23A-23A. AMER SOC HEMATOLOGY, 2001.
       Link to Item
    • Morse, M. A., D. Rizzieri, A. C. Hobeika, N. Chao, and H. Kirn Lyerly. “Dendritic cell (DC) reconstitution after nonmyeloablative allogeneic stem cell transplants.” In Blood, Vol. 96, 2000.
    • Morse, M. A., D. Rizzieri, A. C. Hobeika, N. Chao, and H. K. Lyerly. “Dendritic cell (DC) reconstitution after non-myeloablative allogeneic stem cell transplants.” In Blood, 96:305B-305B. AMER SOC HEMATOLOGY, 2000.
       Link to Item
    • Mosca, P. J., A. C. Hobeika, T. M. Clay, S. K. Nair, E. K. Thomas, D. A. Caron, H. K. Lyerly, and M. A. Morse. “Multiple signals are required for IL-12 production by Flt-3 ligand mobilized dendritic cells.” In Blood, 96:295A-295A. AMER SOC HEMATOLOGY, 2000.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.